Document:

SECURITIES
PURCHASE AGREEMENT

This Securities
Purchase Agreement (this “Agreement”) is dated as of July 3, 2018, between BioVie Inc., a Nevada corporation
(the “Company”), Acuitas Group Holdings, LLC (“Acuitas”) and the purchasers identified on
the signature pages hereto (together with Acuitas, collectively, the “Purchasers”).

WHEREAS, subject
to the terms and conditions set forth in this Agreement and pursuant to an exemption from the registration requirements of Section
5 of the Securities Act of 1933, as amended (the “Securities Act”) contained in Section 4(a)(2) thereof and/or
Regulation D thereunder, the Company desires to issue and sell to the Purchasers, and the Purchasers desire to purchase from the
Company, securities of the Company as more fully described in this Agreement.

NOW, THEREFORE,
IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt
and adequacy of which are hereby acknowledged, the Company and the Purchasers agree as follows:

ARTICLE I.

DEFINITIONS

1.1 
 Definitions. In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the
following terms have the meanings set forth in this Section 1.1:

“Acquiring
Person” shall have the meaning ascribed to such term in Section 4.5.

“Action”
shall have the meaning ascribed to such term in Section 3.1(j).

“Affiliate”
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common
control with a Person as such terms are used in and construed under Rule 405 under the Securities Act.

“Amendment
to Articles” shall have the meaning ascribed to such term in Section 2.2(a)(vii).

“Board
of Directors” means the board of directors of the Company.

“Business
Day” means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or
any day on which banking institutions in the State of New York are authorized or required by law or other governmental action to
close.

“Closing”
means the closing of the purchase and sale of the Securities pursuant to Section 2.1.

“Closing
Date” means the Trading Day on which all of the Transaction Documents have been executed and delivered by the applicable
parties thereto, and all

     -1-

     

    

conditions precedent to (i) the
Purchasers’ obligations to pay the Subscription Amount and (ii) the Company’s obligations to deliver the Securities,
in each case, have been satisfied or waived.

“Commission”
means the United States Securities and Exchange Commission.

“Common
Stock” means the common stock of the Company, $0.0001 par value, and any other class of securities into which such securities
may hereafter be reclassified or changed.

“Common
Stock Equivalents” means any securities of the Company or the Subsidiaries which would entitle the holder thereof to
acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument
that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common
Stock.

“Company
Counsel” means Brown Gee & Wenger LLP, 200 Pringle Avenue, Suite 400, Walnut Creek CA 94596.

“Conversion
Rate” means the number of shares of Common Stock each share of Preferred Stock shall be convertible into, which shall
initially be one hundred (100) shares of Common Stock. In the event that the Per Share Purchase Price is adjusted pursuant to Section
2.4(a), then the “Conversion Rate” shall be equal to (i) the Conversion Rate multiplied by (ii) the ratio of
(A) the initial Per Share Purchase Price as the numerator and (B) the Per Share Purchase Price as adjusted pursuant to Section
2.4(a) as the denominator.

“Disclosure
Schedules” means the Disclosure Schedules of the Company delivered concurrently herewith.

“Disqualification
Event” shall have the meaning ascribed to such term in Section 3.1(oo).

“Evaluation
Date” shall have the meaning ascribed to such term in Section 3.1(s).

“Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

“Exempt
Issuance” means the issuance of (a) Common Stock or options to employees, officers or directors of the Company pursuant
to any share or option plan duly adopted for such purpose, by a majority of the non-employee members of the Board of Directors
or a majority of the members of a committee of non-employee directors established for such purpose for services rendered to the
Company, (b) securities issued hereunder and/or securities upon the exercise or exchange of or conversion of any Securities issued
hereunder and/or other securities exercisable or exchangeable for or convertible into Common Stock issued and outstanding on the
date of this Agreement, provided that such securities have not been amended since the date of this Agreement to increase the number
of such securities or to decrease the exercise price, exchange price or

     -2-

     

    

conversion price of such securities
(other than in connection with share splits or combinations) or to extend the term of such securities, and (c) securities issued
pursuant to acquisitions or strategic transactions approved by a majority of the disinterested directors of the Company, provided
that such securities are issued as “restricted securities” (as defined in Rule 144) and carry no registration rights
that require or permit the filing of any registration statement in connection therewith, and provided that any such issuance shall
only be to a Person (or to the equityholders of a Person) which is, itself or through its subsidiaries, an operating company or
an owner of an asset in a business synergistic with the business of the Company and shall provide to the Company additional benefits
in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities primarily
for the purpose of raising capital or to an entity whose primary business is investing in securities.

“FCPA”
means the Foreign Corrupt Practices Act of 1977, as amended.

“Funding
Date” shall have the meaning ascribed to such term in Section 4.1.

“Funding
Sources” shall have the meaning ascribed to such term in Section 4.1.

“GAAP”
shall have the meaning ascribed to such term in Section 3.1(h).

“Indebtedness”
shall have the meaning ascribed to such term in Section 3.1(aa).

“Intellectual
Property Rights” shall have the meaning ascribed to such term in Section 3.1(p).

“Issuer
Covered Person” shall have the meaning ascribed to such term in Section 3.1(oo).

“Legend
Removal Date” shall have the meaning ascribed to such term in Section 4.1(d).

“Liens”
means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.

“Loeb”
means Loeb & Loeb LLP, with offices located at 345 Park Avenue, New York, New York 10154.

“Material
Adverse Effect” shall have the meaning assigned to such term in Section 3.1(b).

“Material
Permits” shall have the meaning ascribed to such term in Section 3.1(n).

“Per
Preferred Share Purchase Price” equals the Per Share Purchase Price multiplied by the Conversion Rate, subject to adjustment
as set forth herein.

“Per
Share Purchase Price” equals $0.015, subject to adjustment as set forth herein.

     -3-

     

    

“Person”
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint share company, government (or an agency or subdivision thereof) or other entity of any kind.

“Preferred
Shares” means the shares of Preferred Stock issued or issuable to the Purchasers pursuant to this Agreement.

“Preferred
Stock” means shares of the Company’s Series A Convertible Preferred Stock, par value $0.001 per share, having the
rights, preferences and privileges set forth in the Certificate of Designation, in the form of Exhibit C hereto.

“Proceeding”
means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial
proceeding, such as a deposition), whether commenced or threatened.

“Purchaser
Party” shall have the meaning ascribed to such term in Section 4.7.

“Required
Approvals” shall have the meaning ascribed to such term in Section 3.1(e).

“Required
Additional Amount” shall have the meaning ascribed to such term in Section 4.1.

“Required
Funds” shall have the meaning ascribed to such term in Section 4.1.

“Rule
144” means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose
and effect as such Rule.

“SEC
Reports” shall have the meaning ascribed to such term in Section 3.1(h).

“Securities”
means collectively, the Preferred Shares, the Shares, the Warrants and the Warrant Shares.

“Securities
Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

“Shareholder
Approval” shall have the meaning ascribed to such term in Section 2.2(a)(v).

“Shares”
means the shares of Common Stock issued or issuable to the Purchasers upon the conversion of the Preferred Shares or otherwise
pursuant to this Agreement.

“Short
Sales” means all “short sales” as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall
not be deemed to include locating and/or borrowing Common Stock). 

     -4-

     

    

“Subscription
Amount” means, as to the Purchasers, the amount to be paid for the Preferred Shares and Warrants purchased hereunder
in United States dollars and in immediately available funds.

“Subsidiary”
means any subsidiary of the Company and shall, where applicable, also include any direct or indirect subsidiary of the Company
formed or acquired after the date hereof.

“Trading
Day” means a day on which the principal Trading Market is open for trading.

“Trading
Market” means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on
the date in question: the NYSE American (formerly known as the NYSE MKT), the Nasdaq Capital Market, the Nasdaq Global Market,
the Nasdaq Global Select Market, the New York Stock Exchange, the OTCQB or the OTCQX (or any successors to any of the foregoing).

“Transaction
Documents” means this Agreement, the Warrants, all exhibits and schedules hereto and thereto and any other documents
or agreements executed in connection with the transactions contemplated hereunder.

“Transfer
Agent” means West Coast Stock Transfer, Inc., the current transfer agent of the Company, with a mailing address of Attention:
Frank Brickell, 721 N. Vulcan Drive, Suite 205, Encinitas, CA 92024, and any successor transfer agent of the Company.

“Variable
Rate Transaction” shall have the meaning ascribed to such term in Section 4.12.

“VWAP”
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding
date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading
Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if the Common Stock is not then listed or
quoted for trading on a Trading Market and if prices for the Common Stock are then reported in the “Pink Sheets” published
by OTC Markets Group, Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the most recent
bid price per share of the Common Stock so reported, or (c) in all other cases, the fair market value of a share of Common
Stock as determined by an independent appraiser selected in good faith by the Purchasers of a majority in interest of the Securities
then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.

“Warrants”
means the Common Stock purchase warrants delivered to the Purchasers at the Closing in accordance with Section 2.2(a) hereof, which
Warrants shall be exercisable commencing six (6) months following the Closing Date and have a term of six years following the Closing
Date, in the form of Exhibit A attached hereto.

     -5-

     

    

“Warrant
Shares” means, collectively, the shares of Common Stock issuable upon exercise of the Warrants.

ARTICLE II.

PURCHASE AND SALE

2.1 
Closing. On the Closing Date, upon the terms and subject to the conditions set forth herein, the Company agrees to
sell, and the Purchasers agree to purchase, (i) up to an aggregate of $3,200,000 of Preferred Shares and (ii) the Warrants.
The Company shall deliver to the Purchasers the Preferred Shares and the Warrants as determined pursuant to Section 2.2(a), and
the Company and the Purchaser shall deliver the other items set forth in Section 2.2 deliverable at the Closing. Upon satisfaction
of the covenants and conditions set forth in Sections 2.2 and 2.3, the Closing shall occur at the offices of Loeb or such other
location as the parties shall mutually agree.

2.2 
Deliveries.

(a)              
On or prior to the Closing Date, the Company shall deliver or cause to be delivered to the Purchasers the following:

(i)                
this Agreement duly executed by the Company;

(ii)             
a legal opinion of Company Counsel, in a form satisfactory to Acuitas;

(iii)           
a Warrant registered in the name of such Purchaser to purchase up to a number of shares of Common Stock equal to the number
of Shares issuable upon the conversion of the Preferred Shares purchased by such Purchaser on the Closing Date, with an exercise
price equal to 120% of the Per Share Purchase Price, subject to adjustment therein;

(iv)            
a certificate representing the Preferred Shares registered in the name of each Purchaser equal to the amount specified on
its respective signature page hereto divided by the Per Preferred Share Purchase Price (rounded down to the nearest whole share);

(v)              
evidence that stockholders have approved an amendment to the Company’s articles of incorporation to increase the number
of authorized shares to 800,000,000 (the “Shareholder Approval”); and

(vi)            
evidence that Mr. Terren Peizer (or his designee) shall have been appointed to the Company’s board of directors.

(b)              
On or prior to the Closing Date, each Purchaser shall deliver or cause to be delivered to the Company the following:

(i)                
this Agreement duly executed by such Purchaser; and

     -6-

     

    

(ii)             
the consideration specified on such Purchaser’s signature page hereto which shall be wired to the account specified
by the Company.

2.3 
Closing Conditions.

(a)              
The obligations of the Company hereunder in connection with the Closing are subject to the following conditions being met:

(i)                
the accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material
Adverse Effect, in all respects) on the Closing Date of the representations and warranties of the Purchasers contained herein (unless
as of a specific date therein in which case they shall be accurate as of such date);

(ii)             
all obligations, covenants and agreements of the Purchasers required to be performed at or prior to the Closing Date shall
have been performed; and

(iii)           
the delivery by the Purchasers of the items set forth in Section 2.2(b) of this Agreement.

(b)              
The respective obligations of the the Purchasers hereunder in connection with the Closing are subject to the following conditions
being met:

(i)                
the accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material
Adverse Effect, in all respects) when made and on the Closing Date of the representations and warranties of the Company contained
herein (unless as of a specific date therein in which case they shall be accurate as of such date);

(ii)             
all obligations, covenants and agreements of the Company required to be performed at or prior to the Closing Date shall
have been performed;

(iii)           
the delivery by the Company of the items set forth in Section 2.2(a) of this Agreement;

(iv)            
there shall have been no Material Adverse Effect with respect to the Company since the date hereof; and

(v)              
from the date hereof to the Closing Date, trading in the Common Stock shall not have been suspended by the Commission or
the Company’s principal Trading Market, and, at any time prior to the Closing Date, trading in securities generally as reported
by Bloomberg L.P. shall not have been suspended or limited, or minimum prices shall not have been established on securities whose
trades are reported by such service, or on any Trading Market, nor shall a banking moratorium have been declared either by the
United States or New York State authorities nor shall there have occurred any material outbreak or escalation of hostilities or
other national or international calamity of such magnitude in its

     -7-

     

    

effect on, or any material adverse
change in, any financial market which, in each case, in the reasonable judgment of Acuitas, makes it impracticable or inadvisable
to purchase the Securities at the Closing.

2.4 
Purchase Price Adjustments.

(a)              
In the event that the VWAP per share of Common Stock on the Trading Market for the five Trading Days following the date
on which the Form 8-K required by Section 4.4 is filed is less than the Per Share Purchase Price, then the Per Share Purchase Price
and the Per Preferred Share Purchase Price shall be adjusted to be equal the VWAP per share of Common Stock on the Trading Market
for the five Trading Days following the date on which the Form 8-K required by Section 4.4 is filed for all purposes under this
Agreement. The Exercise Price (as defined in the Warrants) under the Warrants and the number of Warrant Shares issuable upon the
exercise of the Warrant shall be ajdusted to reflect the adjusted Per Share Purchase Price.

(b)              
In the event Mallincrokdt or any other party challenging the intellectual property rights of the Company shall prevail in
any proceeding which results in the useful life of the Company’s current intellectual property rights being reduced by more
than 75%, then the Company agrees to deliver to the Purchasers additional Shares and Warrants such that the effective Per Share
Purchase Price (after giving effect to any adjustment required by paragraph (a) above) shall be equal to 50% of the then effective
Per Share Purchase Price and thereafter the “Per Share Purchase Price” shall for all purposes of this Agreement be
50% of the then effective Per Share Purchase Price.

ARTICLE III.

REPRESENTATIONS AND WARRANTIES

3.1       
Representations and Warranties of the Company. Except as disclosed in (i) the SEC Reports prior to the date of this
Agreement (excluding any risk factor disclosure and disclosure of risks included in any “forward-looking statements”
disclaimer or other statements included in such SEC Reports to the extent that they are predictive, forward-looking or primarily
cautionary in nature, in each case other than any specific factual information contained therein, and excluding any supplement,
modification or amendment thereto made after the date hereof) or (ii) the Disclosure Schedules, which Disclosure Schedules shall
be deemed a part hereof and shall qualify any representation or otherwise made herein to the extent of the disclosure contained
therein, the Company hereby makes the following representations and warranties to the Purchasers:

(a)              
Subsidiaries. All of the direct and indirect Subsidiaries of the Company and their respective jurisdictions of incorporation
are set forth on Schedule 3.1(a). The Company owns, directly or indirectly, all of the share capital or other equity interests
of each Subsidiary free and clear of any Liens, and all of the issued and outstanding shares of share capital of each Subsidiary
are validly issued and are fully paid, non-assessable and free of preemptive and similar rights to subscribe for or purchase securities.

     -8-

     

    

(b)              
Organization and Qualification. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise
organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization, with
the requisite power and authority to own and use its properties and assets and to carry on its business as currently conducted.
Neither the Company nor any Subsidiary is in violation nor default of any of the provisions of its respective certificate or articles
of incorporation, bylaws or other organizational or charter documents. Each of the Company and the Subsidiaries is duly qualified
to conduct business and is in good standing as a foreign corporation or other entity in each jurisdiction in which the nature of
the business conducted or property owned by it makes such qualification necessary, except where the failure to be so qualified
or in good standing, as the case may be, could not have or reasonably be expected to result in: (i) a material adverse effect on
the legality, validity or enforceability of any Transaction Document, (ii) a material adverse effect on the results of operations,
assets, business, prospects or condition (financial or otherwise) of the Company and the Subsidiaries, taken as a whole, or (iii)
a material adverse effect on the Company’s ability to perform in any material respect on a timely basis its obligations under
any Transaction Document (any of (i), (ii) or (iii), a “Material Adverse Effect”) and no Proceeding has been
instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and authority
or qualification.

(c)              
Authorization; Enforcement. The Company has the requisite corporate power and authority to enter into and to consummate
the transactions contemplated by this Agreement and each of the other Transaction Documents and otherwise to carry out its obligations
hereunder and thereunder. The execution and delivery of this Agreement and each of the other Transaction Documents by the Company
and the consummation by it of the transactions contemplated hereby and thereby have been duly authorized by all necessary action
on the part of the Company and no further action is required by the Company, the Board of Directors or the Company’s shareholders
in connection herewith or therewith other than in connection with the Required Approvals. This Agreement and each other Transaction
Document to which it is a party has been (or upon delivery will have been) duly executed by the Company and, when delivered in
accordance with the terms hereof and thereof, will constitute the valid and binding obligation of the Company enforceable against
the Company in accordance with its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency,
reorganization, moratorium and other laws of general application affecting enforcement of creditors’ rights generally, (ii)
as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii)
insofar as indemnification and contribution provisions may be limited by applicable law.

(d)              
No Conflicts. The execution, delivery and performance by the Company of this Agreement and the other Transaction
Documents to which it is a party, the issuance and sale of the Securities and the consummation by it of the transactions contemplated
hereby and thereby do not and will not (i) conflict with or violate any provision of the Company’s or any Subsidiary’s
certificate or articles of incorporation, bylaws or other organizational or charter documents, (ii) conflict with, or constitute
a default (or an event that with notice or lapse of time or both would become a default)

     -9-

     

    

under, result in the creation
of any Lien upon any of the properties or assets of the Company or any Subsidiary, or give to others any rights of termination,
amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt
or other instrument (evidencing a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary
is a party or by which any property or asset of the Company or any Subsidiary is bound or affected, or (iii) subject to the Required
Approvals, conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction
of any court or governmental authority to which the Company or a Subsidiary is subject (including federal and state securities
laws and regulations), or by which any property or asset of the Company or a Subsidiary is bound or affected; except in the case
of each of clauses (ii) and (iii), such as could not have or reasonably be expected to result in a Material Adverse Effect.

(e)              
Filings, Consents and Approvals. The Company is not required to obtain any consent, waiver, authorization or order
of, give any notice to, or make any filing or registration with, any court or other federal, state, local or other governmental
authority or other Person in connection with the execution, delivery and performance by the Company of the Transaction Documents,
other than: (i) the filings required pursuant to Sections 4.4 and 4.6 of this Agreement, (ii) application(s) to each applicable
Trading Market for the listing of the Shares and the Warrant Shares for trading thereon in the time and manner required thereby,
and (iii) the filing of a Form D with the Commission and such filings as are required to be made under applicable state securities
laws (collectively, the “Required Approvals”).

(f)               
Issuance of the Securities; Registration. The Securities are duly authorized and, when issued and paid for in accordance
with the applicable Transaction Documents, will be duly and validly issued, fully paid and nonassessable, free and clear of all
Liens imposed by the Company. The Warrant Shares, when issued in accordance with the terms of the Warrants, will be validly issued,
fully paid and nonassessable, free and clear of all Liens imposed by the Company. Following the Shareholder Approval and the Amendment
to Articles, the Company shall have reserved from its duly authorized share capital the maximum number of Common Stock issuable
pursuant to this Agreement, the conversion of the Preferred Shares, and the Warrants.

(g)              
Capitalization. The Company has not issued any shares of Common Stock of its available share capital since its most
recently filed periodic report under the Exchange Act, other than pursuant to (i) the exercise of employee share options under
the Company’s share option plans, the issuance of shares of Common Stock to employees pursuant to the Company’s employee
share purchase plans, (ii) the conversion and/or exercise of Common Stock Equivalents outstanding as of the date of the most
recently filed periodic report under the Exchange Act, and (iii) as set forth in Schedule 3.1(g)(i). No Person has
any right of first refusal, preemptive right, right of participation, or any similar right to participate in the transactions contemplated
by the Transaction Documents. Except as set forth on Schedule 3.1(g)(ii), there are no outstanding options, warrants, scrip
rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities, rights or obligations convertible
into or exercisable or

     -10-

     

    

exchangeable for, or giving any
Person any right to subscribe for or acquire, any shares of Common Stock or the share capital of any Subsidiary, or contracts,
commitments, understandings or arrangements by which the Company or any Subsidiary is or may become bound to issue additional shares
of Common Stock or Common Stock Equivalents or share capital of any Subsidiary. The issuance and sale of the Securities will not
obligate the Company, any Subsidiary to issue shares of Common Stock or other securities to any Person (other than the Purchasers)
and will not result in a right of any holder of Company securities to adjust the exercise, conversion, exchange or reset price
under any of such securities. There are no outstanding securities or instruments of the Company or any Subsidiary that contain
any redemption or similar provisions, and there are no contracts, commitments, understandings or arrangements by which the Company
or any Subsidiary is or may become bound to redeem a security of the Company or such Subsidiary. The Company does not have any
share appreciation rights or “phantom share” plans or agreements or any similar plan or agreement. All of the outstanding
shares of share capital of the Company are duly authorized, validly issued, fully paid and nonassessable, have been issued in compliance
with all federal and state securities laws, and none of such outstanding shares was issued in violation of any preemptive rights
or similar rights to subscribe for or purchase securities. No further approval or authorization of any shareholder, the Board of
Directors or others is required for the issuance and sale of the Securities. There are no shareholders agreements, voting agreements
or other similar agreements with respect to the Company’s share capital to which the Company is a party or, to the knowledge
of the Company, between or among any of the Company’s shareholders.

(h)              
SEC Reports; Financial Statements. To its knowledge, the Company has filed all reports, schedules, forms, statements
and other documents required to be filed by the Company under the Securities Act and the Exchange Act (other than any filings pursuant
to Section 16 of the Exchange Act), including pursuant to Section 13(a) or 15(d) thereof, for the two years preceding the date
hereof (or such shorter period as the Company was required by law or regulation to file such material) (the foregoing materials,
including the exhibits thereto and documents incorporated by reference therein being collectively referred to herein as the “SEC
Reports”) on a timely basis or has received a valid extension of such time of filing and has filed any such SEC Reports
prior to the expiration of any such extension. As of their respective dates, the SEC Reports complied in all material respects
with the requirements of the Securities Act and the Exchange Act, as applicable, and none of the SEC Reports, when filed, contained
any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order
to make the statements therein, in the light of the circumstances under which they were made, not misleading. The financial statements
of the Company included in the SEC Reports comply in all material respects with applicable accounting requirements and the rules
and regulations of the Commission with respect thereto as in effect at the time of filing. Such financial statements have been
prepared in accordance with United States generally accepted accounting principles applied on a consistent basis during the periods
involved (“GAAP”), except as may be otherwise specified in such financial statements or the notes thereto and
except that unaudited financial statements may not contain all footnotes required by GAAP, and fairly present in all material respects
the financial position of the Company and its consolidated

     -11-

     

    

Subsidiaries as of and for the
dates thereof and the results of operations and cash flows for the periods then ended, subject, in the case of unaudited statements,
to normal, immaterial, year-end audit adjustments.

(i)                
Material Changes; Undisclosed Events, Liabilities or Developments. Since the date of the latest audited financial
statements included within the SEC Reports, except as set forth on Schedule 3.1(i) or specifically disclosed in a subsequent SEC
Report filed prior to the date hereof, (i) there has been no event, occurrence or development that has had or that could reasonably
be expected to result in a Material Adverse Effect, (ii) neither the Company nor any Subsidiary has incurred any liabilities (contingent
or otherwise) other than (A) trade payables and accrued expenses incurred in the ordinary course of business consistent with past
practice and (B) liabilities not required to be reflected in the Company’s financial statements pursuant to GAAP or disclosed
in filings made with the Commission, (iii) the Company has not altered its method of accounting, (iv) the Company has not declared
or made any dividend or distribution of cash or other property to its shareholders or purchased, redeemed or made any agreements
to purchase or redeem any shares of its share capital and (v) the Company has not issued any equity securities to any officer,
director or Affiliate, except pursuant to existing Company share option plans, as set forth on Schedule 3.1(i) or as contemplated
by this Agreement. The Company does not have pending before the Commission any request for confidential treatment of information.
Except for the issuance of the Securities contemplated by this Agreement or as disclosed in the SEC Reports, no event, liability,
fact, circumstance, occurrence or development has occurred or exists or is reasonably expected to occur or exist with respect to
the Company or its Subsidiaries or their respective businesses, prospects, properties, operations, assets or financial condition
that would be required to be disclosed by the Company under applicable securities laws at the time this representation is made
or deemed made that has not been publicly disclosed at least one (1) Trading Day prior to the date that this representation is
made.

(j)                
Litigation. Except as set forth on Schedule 3.1(j), there is no action, suit, inquiry, notice of violation, proceeding
or investigation pending or, to the knowledge of the Company, threatened against or affecting the Company or any Subsidiary or
any of their respective properties before or by any court, arbitrator, governmental or administrative agency or regulatory authority
(federal, state, county, local or foreign) (collectively, an “Action”). None of the Actions set forth on Schedule
3.1(j), (i) adversely affects or challenges the legality, validity or enforceability of any of the Transaction Documents or the
Securities or (ii) could, if there were an unfavorable decision, have or reasonably be expected to result in a Material Adverse
Effect. Neither the Company nor any Subsidiary, nor any director or officer thereof, is or has been the subject of any Action involving
a claim of violation of or liability under federal or state securities laws or a claim of breach of fiduciary duty. There has not
been, and to the knowledge of the Company, there is not pending or contemplated, any investigation by the Commission involving
the Company or any current or former director or officer of the Company. The Commission has not issued any stop order or other
order suspending the effectiveness of any registration statement filed by the Company or any Subsidiary under the Exchange Act
or the Securities Act.

     -12-

     

    

(k)              
Labor Relations. No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of
the employees of the Company or any Subsidiary, which could reasonably be expected to result in a Material Adverse Effect. None
of the Company’s or its Subsidiaries’ employees is a member of a union that relates to such employee’s relationship
with the Company or such Subsidiary, and neither the Company nor any of its Subsidiaries is a party to a collective bargaining
agreement, and the Company and its Subsidiaries believe that their relationships with their employees are good. To the knowledge
of the Company, no executive officer of the Company or any Subsidiary, is, or is now expected to be, in violation of any material
term of any employment contract, confidentiality, disclosure or proprietary information agreement or non-competition agreement,
or any other contract or agreement or any restrictive covenant in favor of any third party, and the continued employment of each
such executive officer does not subject the Company or any of its Subsidiaries to any liability with respect to any of the foregoing
matters. The Company and its Subsidiaries are in compliance with all U.S. federal, state, local and foreign laws and regulations
relating to employment and employment practices, terms and conditions of employment and wages and hours, except where the failure
to be in compliance could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.

(l)                
Compliance. Neither the Company nor any Subsidiary: (i) is in default under or in violation of (and no event has
occurred that has not been waived that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary
under), nor has the Company or any Subsidiary received notice of a claim that it is in default under or that it is in violation
of, any indenture, loan or credit agreement or any other agreement or instrument to which it is a party or by which it or any of
its properties is bound (whether or not such default or violation has been waived), (ii) is in violation of any judgment, decree
or order of any court, arbitrator or other governmental authority or (iii) is or has been in violation of any statute, rule, ordinance
or regulation of any governmental authority, including without limitation all foreign, federal, state and local laws relating to
taxes, environmental protection, occupational health and safety, product quality and safety and employment and labor matters, except
in each case as could not have or reasonably be expected to result in a Material Adverse Effect.

(m)            
Environmental Laws.The Company and its Subsidiaries (i) are in compliance with all federal, state, local and
foreign laws relating to pollution or protection of human health or the environment (including ambient air, surface water, groundwater,
land surface or subsurface strata), including laws relating to emissions, discharges, releases or threatened releases of chemicals,
pollutants, contaminants, or toxic or hazardous substances or wastes (collectively, “Hazardous Materials”) into
the environment, or otherwise relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport
or handling of Hazardous Materials, as well as all authorizations, codes, decrees, demands, or demand letters, injunctions, judgments,
licenses, notices or notice letters, orders, permits, plans or regulations, issued, entered, promulgated or approved thereunder
(“Environmental Laws”); (ii) have received all permits, licenses or other approvals required of them under applicable
Environmental Laws to conduct their respective businesses; and (iii) are in compliance with all terms and conditions of any such
permit, license or approval where in each clause (i), (ii) and (iii),

     -13-

     

    

the failure to so comply could
be reasonably expected to have, individually or in the aggregate, a Material Adverse Effect.

(n)              
Regulatory Permits. The Company and the Subsidiaries possess all certificates, authorizations and permits issued
by the appropriate federal, state, local or foreign regulatory authorities necessary to conduct their respective businesses as
described in the SEC Reports, except where the failure to possess such permits could not reasonably be expected to result in a
Material Adverse Effect (“Material Permits”), and neither the Company nor any Subsidiary has received any notice
of proceedings relating to the revocation or modification of any Material Permit.

(o)              
Title to Assets. The Company and the Subsidiaries have good and marketable title in fee simple to all real property
owned by them and good and marketable title in all personal property owned by them that is material to the business of the Company
and the Subsidiaries, in each case free and clear of all Liens, except for (i) Liens as do not materially affect the value of such
property and do not materially interfere with the use made and proposed to be made of such property by the Company and the Subsidiaries
and (ii) Liens for the payment of federal, state or other taxes, for which appropriate reserves have been made therefor in accordance
with GAAP, and the payment of which is neither delinquent nor subject to penalties. Any real property and facilities held under
lease by the Company and the Subsidiaries are held by them under valid, subsisting and enforceable leases with which the Company
and the Subsidiaries are in material compliance.

(p)              
Intellectual Property. The Company and the Subsidiaries have, or have rights to use, all patents, patent applications,
trademarks, trademark applications, service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual
property rights and similar rights necessary or required for use in connection with their respective businesses as described in
the SEC Reports and which the failure to so have could have a Material Adverse Effect (collectively, the “Intellectual
Property Rights”). None of the Company or any Subsidiary has received a notice (written or otherwise) that any of, the
Intellectual Property Rights has expired, terminated or been abandoned, or is expected to expire or terminate or be abandoned,
within two (2) years from the date of this Agreement. Neither the Company nor any Subsidiary has received, since the date of the
latest audited financial statements included within the SEC Reports, a written notice of a claim or otherwise has any knowledge
that the Intellectual Property Rights violate or infringe upon the rights of any Person, except as could not have or reasonably
be expected to not have a Material Adverse Effect. To the knowledge of the Company, all such Intellectual Property Rights are enforceable
and there is no existing infringement by another Person of any of the Intellectual Property Rights. The Company and its Subsidiaries
have taken reasonable security measures to protect the secrecy, confidentiality and value of all of their intellectual properties,
except where failure to do so could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.

(q)              
Insurance. The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against
such losses and risks and in such amounts as

     -14-

     

    

are prudent and customary in the
businesses in which the Company and the Subsidiaries are engaged including, but not limited to, directors and officers insurance
coverage in such amount as is customary for companies engaged in the type of business conducted by the Company nor any Subsidiary.
Neither the Company nor any Subsidiary has any reason to believe that it will not be able to renew its existing insurance coverage
as and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business
without a significant increase in cost.

(r)               
Transactions With Affiliates and Employees. Except as set forth in the SEC Reports, none of the officers or directors
of the Company or any Subsidiary and, to the knowledge of the Company, none of the employees of the Company or any Subsidiary is
presently a party to any transaction with the Company or any Subsidiary (other than for services as employees, officers and directors),
including any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental
of real or personal property to or from, providing for the borrowing of money from or lending of money to or otherwise requiring
payments to or from any officer, director or such employee or, to the knowledge of the Company, any entity in which any officer,
director, or any such employee has a substantial interest or is an officer, director, trustee, shareholder, member or partner,
in each case in excess of $120,000 other than for (i) payment of salary or consulting fees for services rendered, (ii) reimbursement
for expenses incurred on behalf of the Company and (iii) other employee benefits, including share option agreements under any share
option plan of the Company.

(s)               
Sarbanes-Oxley; Internal Accounting Controls. The Company and the Subsidiaries are in material compliance with any
and all applicable requirements of the Sarbanes-Oxley Act of 2002 that are effective as of the date hereof, and any and all applicable
rules and regulations promulgated by the Commission thereunder that are effective as of the date hereof and as of the Closing Date.
Except as set forth in the SEC Reports, each of the Company and the Subsidiaries maintains a system of internal accounting controls
sufficient to provide reasonable assurance that: (i) transactions are executed in accordance with management’s general or
specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity
with GAAP and to maintain asset accountability, (iii) access to assets is permitted only in accordance with management’s
general or specific authorization, and (iv) the recorded accountability for assets is compared with the existing assets at reasonable
intervals and appropriate action is taken with respect to any differences. Except as set forth in the SEC Reports, each of the
Company and the Subsidiaries has established disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and
15d-15(e)) for the Company and the Subsidiaries and designed such disclosure controls and procedures to ensure that information
required to be disclosed by the Company in the reports it files or submits under the Exchange Act is recorded, processed, summarized
and reported, within the time periods specified in the Commission’s rules and forms. The Company’s certifying officers
have evaluated the effectiveness of the disclosure controls and procedures of the Company and the Subsidiaries as of the end of
the period covered by the most recently filed periodic report under the Exchange Act (such date, the “Evaluation Date”).
The Company presented in its most recently filed periodic report under the Exchange Act the conclusions of the certifying officers
about

     -15-

     

    

the effectiveness of the disclosure
controls and procedures based on their evaluations as of the Evaluation Date. Since the Evaluation Date, there have been no changes
in the internal control over financial reporting (as such term is defined in the Exchange Act) of the Company and its Subsidiaries
that have materially affected, or is reasonably likely to materially affect, the internal control over financial reporting of the
Company and its Subsidiaries.

(t)                
Certain Fees. No brokerage or finder’s fees or commissions are or will be payable by the Company or any Subsidiary
to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank or other Person with respect to
the transactions contemplated by the Transaction Documents. The Purchasers shall have no obligation with respect to any fees or
with respect to any claims made by or on behalf of other Persons for fees of a type contemplated in this Section that may be due
in connection with the transactions contemplated by the Transaction Documents.

(u)              
Investment Company. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for
the Securities, will not be or be an Affiliate of, an “investment company” within the meaning of the Investment Company
Act of 1940, as amended. The Company shall conduct its business in a manner so that it will not become an “investment company”
subject to registration under the Investment Company Act of 1940, as amended.

(v)              
Registration Rights. Except as set forth on Schedule 3.1(v), no Person has any right to cause the Company or any
Subsidiary to effect the registration under the Securities Act of any securities of the Company or any Subsidiary.

(w)            
Listing and Maintenance Requirements. The Common Stock is registered pursuant to Section 12(b) or 12(g) of the Exchange
Act, and the Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the
registration of the Common Stock under the Exchange Act nor has the Company received any notification that the Commission is contemplating
terminating such registration. The Company has not, in the 12 months preceding the date hereof, received notice from any Trading
Market on which the Common Stock is or has been listed or quoted to the effect that the Company is not in compliance with the listing
or maintenance requirements of such Trading Market. The Company is, and has no reason to believe that it will not in the foreseeable
future continue to be, in compliance with all such listing and maintenance requirements. The Common Stock is currently eligible
for electronic transfer through the Depository Trust Company or another established clearing corporation and the Company is current
in payment of the fees to the Depository Trust Company (or such other established clearing corporation) in connection with such
electronic transfer.

(x)              
Application of Takeover Protections. The Company and the Board of Directors have taken all necessary action, if any,
in order to render inapplicable any control share acquisition, business combination, poison pill (including any distribution under
a rights agreement) or other similar anti-takeover provision under the Company’s articles of incorporation (or similar
charter documents) or the laws of its state of

     -16-

     

    

incorporation that is or could
become applicable to the Purchasers as a result of the Purchasers and the Company fulfilling their obligations or exercising their
rights under the Transaction Documents, including without limitation as a result of the Company’s issuance of the Securities
and the Purchasers’ ownership of the Securities.

(y)              
Disclosure. All of the disclosure furnished by or on behalf of the Company to the Purchasers regarding the Company
and its Subsidiaries, their respective businesses and the transactions contemplated hereby, including the Disclosure Schedules
to this Agreement, is true and correct and does not contain any untrue statement of a material fact or omit to state any material
fact necessary in order to make the statements made therein, in the light of the circumstances under which they were made, not
misleading. The press releases disseminated by the Company during the twelve months preceding the date of this Agreement taken
as a whole do not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein
or necessary in order to make the statements therein, in the light of the circumstances under which they were made and when made,
not misleading. The Company acknowledges and agrees that no Purchaser makes or has made any representations or warranties with
respect to the transactions contemplated hereby other than those specifically set forth in Section 3.2 hereof.

(z)              
No Integrated Offering. Assuming the accuracy of the Purchasers’ representations and warranties set forth in
Section 3.2, neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly,
made any offers or sales of any security or solicited any offers to buy any security, under circumstances that would cause this
offering of the Securities to be integrated with prior offerings by the Company for purposes of (i) the Securities Act, which would
require the registration of the Warrants or the Warrant Shares under the Securities Act or (ii) any applicable shareholder approval
provisions of any Trading Market on which any of the securities of the Company are listed or designated.

(aa)           
Solvency. Based on the consolidated financial condition of the Company as of the Closing Date, after giving effect
to the receipt by the Company of the proceeds from the sale of the Securities hereunder, (i) the fair saleable value of the Company’s
assets exceeds the amount that will be required to be paid on or in respect of the Company’s existing debts and other liabilities
(including known contingent liabilities) as they mature, (ii) the Company’s assets do not constitute unreasonably small capital
to carry on its business as now conducted and as proposed to be conducted including its capital needs taking into account the particular
capital requirements of the business conducted by the Company, consolidated and projected capital requirements and capital availability
thereof, and (iii) the current cash flow of the Company, together with the proceeds the Company would receive, were it to liquidate
all of its assets, after taking into account all anticipated uses of the cash, would be sufficient to pay all amounts on or in
respect of its liabilities when such amounts are required to be paid. The Company does not intend to incur debts beyond its ability
to pay such debts as they mature (taking into account the timing and amounts of cash to be payable on or in respect of its debt).
The Company has no knowledge of any facts or circumstances which lead it to believe that it will file for reorganization or liquidation
under the bankruptcy or reorganization

     -17-

     

    

laws of any jurisdiction within one year from the Closing
Date. Schedule 3.1(aa) sets forth as of the date hereof all outstanding secured and unsecured Indebtedness of the Company or any
Subsidiary, or for which the Company or any Subsidiary has commitments. For the purposes of this Agreement, “Indebtedness”
means (x) any liabilities for borrowed money or amounts owed in excess of $50,000 (other than trade accounts payable incurred in
the ordinary course of business), (y) all guaranties, endorsements and other contingent obligations in respect of indebtedness
of others, whether or not the same are or should be reflected in the Company’s consolidated balance sheet (or the notes thereto),
except guaranties by endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course
of business; and (z) the present value of any lease payments in excess of $50,000 due under leases required to be capitalized in
accordance with GAAP. Neither the Company nor any Subsidiary is in default with respect to any Indebtedness

(bb)          
Tax Status. Except for matters that would not, individually or in the aggregate, have or reasonably be expected to
result in a Material Adverse Effect, the Company and its Subsidiaries each (i) has made or filed all United States federal, state
and local income and all foreign income and franchise tax returns, reports and declarations required by any jurisdiction to which
it is subject, (ii) has paid all taxes and other governmental assessments and charges that are material in amount, shown or determined
to be due on such returns, reports and declarations and (iii) has set aside on its books provision reasonably adequate for the
payment of all material taxes for periods subsequent to the periods to which such returns, reports or declarations apply. There
are no unpaid taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the
Company or of any Subsidiary know of no basis for any such claim.

(cc)           
Foreign Corrupt Practices. Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary,
any agent or other person acting on behalf of the Company or any Subsidiary, has (i) directly or indirectly, used any funds for
unlawful contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii)
made any unlawful payment to foreign or domestic government officials or employees or to any foreign or domestic political parties
or campaigns from corporate funds, (iii) failed to disclose fully any contribution made by the Company or any Subsidiary (or made
by any person acting on its behalf of which the Company is aware) which is in violation of law, or (iv) violated in any material
respect any provision of FCPA.

(dd)          
Accountants. The Company’s independent registered public accounting firm is D. Brooks & Associates, CPAS,
PA. To the knowledge and belief of the Company, such accounting firm (i) is a registered public accounting firm as required by
the Exchange Act and (ii) shall express its opinion with respect to the financial statements to be included in the Company’s
Annual Report for the fiscal year ending June 30, 2018.

(ee)           
 Acknowledgment Regarding Purchasers’ Purchase of Securities. The Company acknowledges and agrees that the
Purchasers are acting solely in the capacity of an arm’s length purchaser with respect to the Transaction Documents and the

     -18-

     

    

transactions contemplated thereby.
The Company further acknowledges that Acuitas is not acting as a financial advisor or fiduciary of the Company (or in any similar
capacity) with respect to the Transaction Documents and the transactions contemplated thereby and any advice given by Acuitas or
any of its representatives or agents in connection with the Transaction Documents and the transactions contemplated thereby is
merely incidental to Acuitas’ purchase of the Securities. The Company further represents to the Purchasers that the Company’s
decision to enter into this Agreement and the other Transaction Documents has been based solely on the independent evaluation of
the transactions contemplated hereby by the Company and its representatives.

(ff)             
[RESERVED].

(gg)          
Regulation M Compliance.  The Company has not, and to its knowledge no one acting on its behalf has, (i) taken,
directly or indirectly, any action designed to cause or to result in the stabilization or manipulation of the price of any securities
of the Company to facilitate the sale or resale of any of the Securities, (ii) sold, bid for, purchased, or, paid any compensation
for soliciting purchases of, any of the Securities, or (iii) paid or agreed to pay to any Person any compensation for soliciting
another to purchase any other securities of the Company.

(hh)          
Office of Foreign Assets Control. Neither the Company nor any Subsidiary nor, to the Company's knowledge, any director,
officer, agent, employee or affiliate of the Company or any Subsidiary is currently subject to any U.S. sanctions administered
by the Office of Foreign Assets Control of the U.S. Treasury Department (“OFAC”).

(ii)              
U.S. Real Property Holding Corporation. The Company is not and has never been a U.S. real property holding corporation
within the meaning of Section 897 of the Internal Revenue Code of 1986, as amended, and the Company shall so certify upon Acuitas’
request.

(jj)              
Bank Holding Company Act. Neither the Company nor any of its Subsidiaries, or Affiliates is subject to the Bank Holding
Company Act of 1956, as amended (the “BHCA”) and to regulation by the Board of Governors of the Federal Reserve
System (the “Federal Reserve”). Neither the Company nor any of its Subsidiaries or Affiliates owns or controls,
directly or indirectly, five percent (5%) or more of the outstanding shares of any class of voting securities or twenty-five percent
or more of the total equity of a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve. Neither
the Company nor any of its Subsidiaries or Affiliates exercises a controlling influence over the management or policies of a bank
or any entity that is subject to the BHCA and to regulation by the Federal Reserve.

(kk)          
Money Laundering. The operations of the Company and its Subsidiaries are and have been conducted at all times in
compliance with applicable financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting
Act of 1970, as amended, applicable money laundering statutes and applicable rules and regulations thereunder (collectively, the
“Money Laundering Laws”), and no Action or Proceeding by or before any court or governmental agency, authority
or body or any

     -19-

     

    

arbitrator
involving the Company or any Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of the Company
or any Subsidiary, threatened.

(ll)              
Lock-Up Agreements. The Company has signed a Lock-Up Agreement with each of the Company’s directors and officers
in the form attached hereto as Exhibit B.

(mm)      
Private Placement. Assuming the accuracy of the Purchasers’ representations and warranties set forth in Section
3.2, no registration under the Securities Act is required for the offer and sale of the Securities by the Company to the Purchasers
as contemplated hereby.

(nn)          
No General Solicitation. Neither the Company nor any Person acting on behalf of the Company has offered or
sold any of the Securities by any form of general solicitation or general advertising. The Company has offered the Securities for
sale only to the Purchasers and certain other “accredited investors” within the meaning of Rule 501 under the Securities
Act.

(oo)          
No Disqualification Events. With respect to the Warrants and Warrant Shares to be offered and sold hereunder
in reliance on Rule 506 under the Securities Act, none of the Company, any of its predecessors, any affiliated issuer, any director,
executive officer, other officer of the Company participating in the offering hereunder, any beneficial owner of 20% or more of
the Company’s outstanding voting equity securities, calculated on the basis of voting power, nor any promoter (as that term
is defined in Rule 405 under the Securities Act) connected with the Company in any capacity at the time of sale (each, an “Issuer
Covered Person”) is subject to any of the “Bad Actor” disqualifications described in Rule 506(d)(1)(i) to
(viii) under the Securities Act (a “Disqualification Event”), except for a Disqualification Event covered by
Rule 506(d)(2) or (d)(3). The Company has exercised reasonable care to determine whether any Issuer Covered Person is subject to
a Disqualification Event. The Company has complied, to the extent applicable, with its disclosure obligations under Rule 506(e),
and has furnished to the Purchasers a copy of any disclosures provided thereunder.

(pp)          
Other Covered Persons. The Company is not aware of any person (other than any Issuer Covered Person) that
has been or will be paid (directly or indirectly) remuneration for solicitation of purchasers in connection with the sale of any
Securities.

(qq)          
Notice of Disqualification Events. The Company will notify the Purchasers in writing, prior to the Closing
Date of (i) any Disqualification Event relating to any Issuer Covered Person and (ii) any event that would, with the passage of
time, reasonably be expected to become a Disqualification Event relating to any Issuer Covered Person, in each case of which it
is aware.

The Purchasers acknowledge
and agree that the representations contained in Section 3.1 shall not modify, amend or affect the Company’s right to rely
on the Purchasers’ representations and warranties contained in this Agreement or any representation and warranties contained
in any other Transaction Document or any other document or instrument executed and/or delivered in connection with this Agreement
or the consummation of the transactions contemplated hereby.

     -20-

     

    

3.2 
Representations and Warranties of the Purchasers. Each Purchaser hereby represents and warrants as of the date hereof
and as of the Closing Date to the Company as follows (unless as of a specific date therein, in which case they shall be accurate
as of such date):

(a)              
Organization; Authority. Such Purchaser is an entity duly incorporated or formed, validly existing and in good standing
under the laws of the jurisdiction of its incorporation or formation with full right, corporate, partnership, limited liability
company or similar power and authority to enter into and to consummate the transactions contemplated by the Transaction Documents
and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of the Transaction Documents and
performance by such Purchaser of the transactions contemplated by the Transaction Documents have been duly authorized by all necessary
limited liability company or similar action, on the part of such Purchaser. Each Transaction Document to which it is a party has
been duly executed by such Purchaser, and when delivered by such Purchaser in accordance with the terms hereof, will constitute
the valid and legally binding obligation of such Purchaser, enforceable against it in accordance with its terms, except: (i) as
limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general
application affecting enforcement of creditors’ rights generally, (ii) as limited by laws relating to the availability of
specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions
may be limited by applicable law.

(b)              
Understandings or Arrangements. Such Purchaser is acquiring the Securities as principal for its own account and has
no direct or indirect arrangement or understandings with any other persons to distribute or regarding the distribution of such
Securities (this representation and warranty not limiting such Purchaser’s right to sell the Securities in compliance with
applicable federal and state securities laws). Such Purchaser is acquiring the Shares hereunder in the ordinary course of its business.
Such Purchaser understands that the Warrants and the Warrant Shares are “restricted securities” and have not been registered
under the Securities Act or any applicable state securities law and is acquiring such Securities as principal for its own account
and not with a view to or for distributing or reselling such Securities or any part thereof in violation of the Securities Act
or any applicable state securities law, has no present intention of distributing any of such Securities in violation of the Securities
Act or any applicable state securities law and has no direct or indirect arrangement or understandings with any other persons to
distribute or regarding the distribution of such Securities in violation of the Securities Act or any applicable state securities
law (this representation and warranty not limiting such Purchaser’s right to sell such Securities pursuant to a registration
statement or otherwise in compliance with applicable federal and state securities laws).

(c)              
Purchaser Status. At the time such Purchaser was offered the Securities, it was, and as of the date hereof it is,
either: (i) an “accredited investor” as defined in Rule 501(a)(1), (a)(2), (a)(3), (a)(7) or (a)(8) under the Securities
Act or (ii) a “qualified institutional buyer” as defined in Rule 144A(a) under the Securities Act.

     -21-

     

    

(d)              
Experience of Such Purchaser. Such Purchaser, either alone or together with its representatives, has such knowledge,
sophistication and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective
investment in the Securities, and has so evaluated the merits and risks of such investment. Such Purchaser is able to bear the
economic risk of an investment in the Securities and, at the present time, is able to afford a complete loss of such investment.

(e)              
Access to Information. Such Purchaser acknowledges that it has had the opportunity to review the Transaction Documents
(including all exhibits and schedules thereto) and the SEC Reports and has been afforded, (i) the opportunity to ask such questions
as it has deemed necessary of, and to receive answers from, representatives of the Company concerning the terms and conditions
of the offering of the Securities and the merits and risks of investing in the Securities; (ii) access to information about the
Company and its financial condition, results of operations, business, properties, management and prospects sufficient to enable
it to evaluate its investment; and (iii) the opportunity to obtain such additional information that the Company possesses or can
acquire without unreasonable effort or expense that is necessary to make an informed investment decision with respect to the investment. 

(f)               
Certain Transactions and Confidentiality. Other than consummating the transactions contemplated hereunder, such Purchaser
has not, nor has any Person acting on behalf of or pursuant to any understanding with such Purchaser, directly or indirectly executed
any purchases or sales, including Short Sales, of the securities of the Company during the period commencing as of the time
that such Purchaser first received a term sheet (written or oral) from the Company or any other Person representing the Company
setting forth the material pricing terms of the transactions contemplated hereunder and ending immediately prior to the execution
hereof. Notwithstanding the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio
managers manage separate portions of such Purchaser’s assets and the portfolio managers have no direct knowledge of the investment
decisions made by the portfolio managers managing other portions of such Purchaser’s assets, the representation set forth
above shall only apply with respect to the portion of assets managed by the portfolio manager that made the investment decision
to purchase the Securities covered by this Agreement. Other than to other Persons party to this Agreement or to such Purchaser’s
representatives, including, without limitation, its officers, directors, partners, legal and other advisors, employees, agents
and Affiliates, such Purchaser has maintained the confidentiality of all disclosures made to it in connection with this transaction
(including the existence and terms of this transaction).

The Company acknowledges
and agrees that the representations contained in this Section 3.2 shall not modify, amend or affect such Purchaser’s right
to rely on the Company’s representations and warranties contained in this Agreement or any representations and warranties
contained in any other Transaction Document or any other document or instrument executed and/or delivered in connection with this
Agreement or the consummation of the transactions contemplated hereby.

     -22-

     

    

ARTICLE IV.

OTHER AGREEMENTS OF THE PARTIES

4.1 
Removal of Legends.

(a)              
The Shares, the Warrants and Warrant Shares may only be disposed of in compliance with state and federal securities laws.
In connection with any transfer of the Shares, the Warrants or Warrant Shares other than pursuant to an effective registration
statement or Rule 144, to the Company or to an Affiliate of a Purchaser or in connection with a pledge as contemplated in Section
4.1(b), the Company may require the transferor thereof to provide to the Company an opinion of counsel selected by the transferor
and reasonably acceptable to the Company, the form and substance of which opinion shall be reasonably satisfactory to the Company,
to the effect that such transfer does not require registration of such transferred Warrants or Warrant Shares under the Securities
Act.

(b)              
Each Purchaser agrees to the imprinting, so long as is required by this Section 4.1, of a legend on any of the Shares, Warrants
or Warrant Shares in the following form:

“[NEITHER ]THIS SECURITY
[NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAS] BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR
THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED
(THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT
UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS
OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY [AND THE SECURITIES ISSUABLE UPON
EXERCISE OF THIS SECURITY ]MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT WITH A REGISTERED BROKER-DEALER OR OTHER
LOAN WITH A FINANCIAL INSTITUTION THAT IS AN “ACCREDITED INVESTOR” AS DEFINED IN RULE 501(a) UNDER THE SECURITIES ACT
OR OTHER LOAN SECURED BY SUCH SECURITIES.”

(c)              
The Company acknowledges and agrees that a Purchaser may from time to time pledge pursuant to a bona fide margin agreement
with a registered broker-dealer or grant a security interest in some or all of the Shares, Warrants or Warrant Shares to a financial
institution that is an “accredited investor” as defined in Rule 501(a) under the Securities Act, and if required under
the terms of such arrangement, such Purchaser may transfer pledged or secured Shares, Warrants or Warrant Shares to the pledgees
or secured parties. Such a pledge or transfer would not be subject to approval of the Company and no legal opinion of legal counsel
of the pledgee, secured party or pledgor shall be required in connection therewith. Further, no notice shall be required of such
pledge. At the appropriate Purchaser’s expense, the Company will execute and deliver such reasonable documentation as a pledgee
or secured party of Shares, Warrants and

     -23-

     

    

Warrant Shares may reasonably
request in connection with a pledge or transfer of the Shares, Warrants or Warrant Shares.

(d)              
Certificates evidencing the Shares or Warrant Shares shall not contain any legend (including the legend set forth in Section
4.1(b) hereof): (i) while a registration statement covering the resale of such security is effective under the Securities Act,
or (ii) following any sale of such Shares or Warrant Shares pursuant to Rule 144 (assuming, in the case of the Warrant Shares,
cashless exercise of the Warrants), or (iii) if such Shares or Warrant Shares are eligible for sale under Rule 144 (assuming, in
the case of the Warrant Shares, cashless exercise of the Warrants), or (iv) if such legend is not required under applicable requirements
of the Securities Act (including judicial interpretations and pronouncements issued by the staff of the Commission). The Company
shall cause its counsel to issue a legal opinion to the Transfer Agent or a Purchaser promptly if required by the Transfer Agent
to effect the removal of the legend hereunder, or if requested by a Purchaser. If all or any portion of a Warrant is exercised
at a time when there is an effective registration statement to cover the resale of the Warrant Shares, or if such Shares or Warrant
Shares may be sold under Rule 144 (assuming, in the case of the Warrant Shares, cashless exercise of the Warrants) or if such legend
is not otherwise required under applicable requirements of the Securities Act (including judicial interpretations and pronouncements
issued by the staff of the Commission) then such Warrant Shares shall be issued free of all legends. The Company agrees that following
such time as such legend is no longer required under this Section 4.1(d), the Company will, no later than the earlier of (i) two
(2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined below) following the
delivery by a Purchaser to the Company or the Transfer Agent of a certificate representing Shares or Warrant Shares and such representations
and warranties relating to the “Affiliate” status of such Purchaser and the holding period of the Shares or Warrants
issued with a restrictive legend (such date, the “Legend Removal Date”), deliver or cause to be delivered to
such Purchaser a certificate representing such shares that is free from all restrictive and other legends. The Company may not
make any notation on its records or give instructions to the Transfer Agent that enlarge the restrictions on transfer set forth
in this Section 4. Shares or Warrant Shares subject to legend removal hereunder shall be transmitted by the Transfer Agent to the
applicable Purchaser by crediting the account of such Purchaser’s prime broker with the Depository Trust Company System as
directed by such Purchaser. As used herein, “Standard Settlement Period” means the standard settlement period, expressed
in a number of Trading Days, on the Company’s primary Trading Market with respect to the Common Stock as in effect on the
date of delivery of a certificate representing Shares or Warrant Shares issued with a restrictive legend.

(e)              
In addition to Acutias’ other available remedies, the Company shall pay to Acuitas, in cash, (i) as partial liquidated
damages and not as a penalty, for each $1,000 of Shares or Warrant Shares (based on the volume weighted average price or VWAP of
the Common Stock on the date such securities are submitted to the Transfer Agent) delivered for removal of the restrictive legend
and subject to Section 4.1(d), $10 per Trading Day (increasing to $20 per Trading Day five (5) Trading Days after such damages
have begun to accrue) for each Trading Day after the Legend Removal Date until such certificate is delivered without a legend and
(ii) if the Company fails to (a) issue and deliver (or cause

     -24-

     

    

to be delivered) to Acuitas by
the Legend Removal Date a certificate representing the securities so delivered to the Company by Acuitas that is free from all
restrictive and other legends and (b) if after the Legend Removal Date Acuitas purchases (in an open market transaction or otherwise)
shares of Common Stock to deliver in satisfaction of a sale by Acuitas of all or any portion of the number of shares of Common
Stock, or a sale of a number of shares of Common Stock equal to all or any portion of the number of shares of Common Stock, that
Acuitas anticipated receiving from the Company without any restrictive legend, then an amount equal to the excess of Acuitas’
total purchase price (including brokerage commissions and other out-of-pocket expenses, if any) for the shares of Common Stock
so purchased (including brokerage commissions and other out-of-pocket expenses, if any) (the “Buy-In Price”)
over the product of (A) such number of Shares or Warrant Shares that the Company was required to deliver to Acuitas by the Legend
Removal Date multiplied by (B) the lowest closing sale price of the Common Stock on any Trading Day during the period commencing
on the date of the delivery by Acuitas to the Company of the applicable Shares or Warrant Shares (as the case may be) and ending
on the date of such delivery and payment under this Section 4.1(e).

4.2 
Furnishing of Information. 

(a)              
Until the earlier of (i) the time that Acuitas owns no Securities or (ii) all of the Warrants have expired, the Company
covenants to timely file (or obtain extensions in respect thereof and file within the applicable grace period) all reports required
to be filed by the Company after the date hereof pursuant to the Exchange Act even if the Company is not then subject to the reporting
requirements of the Exchange Act.

(b)              
At any time during the period commencing from the date hereof and ending at such time that all of the Shares or Warrant
Shares (assuming, in the case of the Warrant Shares, cashless exercise) may be sold without the requirement for the Company to
be in compliance with Rule 144(c)(1) and otherwise without restriction or limitation pursuant to Rule 144, if the Company (i) shall
fail for any reason to satisfy the current public information requirement under Rule 144(c) or (ii) fail to satisfy any condition
set forth in Rule 144(i)(2) (a “Public Information Failure”) then, in addition to Acuitas’ other available
remedies, the Company shall pay to Acuitas, in cash, as partial liquidated damages and not as a penalty, by reason of any such
delay in or reduction of its ability to sell the Shares or Warrant Shares, an amount in cash equal to two percent (2.0%) of the
aggregate Exercise Price of Acuitas’ Warrants on the day of a Public Information Failure and on every thirtieth (30th) day
(pro rated for periods totaling less than thirty days) thereafter until the earlier of (a) the date such Public Information Failure
is cured and (b) such time that such public information is no longer required for the Purchaser to transfer the Warrant Shares
pursuant to Rule 144. The payments to which Acuitas shall be entitled pursuant to this Section 4.2(b) are referred to herein as
“Public Information Failure Payments.” Public Information Failure Payments shall be paid on the earlier of (i) the
last day of the calendar month during which such Public Information Failure Payments are incurred and (ii) the third (3rd) Business
Day after the event or failure giving rise to the Public Information Failure Payments is cured. In the event the Company fails
to make Public Information Failure Payments in a timely manner, such Public Information Failure Payments shall bear interest at
the rate of 1.5% per month

     -25-

     

    

(prorated for partial months)
until paid in full. Nothing herein shall limit Acuitas’ right to pursue actual damages for the Public Information Failure,
and Acuitas shall have the right to pursue all remedies available to it at law or in equity including, without limitation, a decree
of specific performance and/or injunctive relief.

4.3 
Integration. The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect
of any security (as defined in Section 2 of the Securities Act) that could reasonably be integrated with the offer or sale of the
Securities for purposes of the rules and regulations of any Trading Market such that it would require shareholder approval prior
to the closing of such other transaction unless shareholder approval is obtained before the closing of such subsequent transaction.

4.4 
Securities Laws Disclosure; Publicity. The Company shall file a Current Report on Form 8-K, including the Transaction
Documents as exhibits thereto, with the Commission after 5:00pm Eastern Daylight Time on the date hereof. The Company and Purchaser
shall consult with each other in issuing any other press releases with respect to the transactions contemplated hereby, and neither
the Company nor Purchaser shall issue any such press release nor otherwise make any such public statement without the prior consent
of the Company, with respect to any press release of Purchaser, or without the prior consent of Purchaser, with respect to any
press release of the Company, which consent shall not unreasonably be withheld or delayed, except if such disclosure is required
by law, in which case the disclosing party shall promptly provide the other party with prior notice of such public statement or
communication. Notwithstanding the foregoing, the Company shall not publicly disclose the name of a Purchaser, or include the name
of a Purchaser in any filing with the Commission or any regulatory agency or Trading Market, without the prior written consent
of such Purchaser, except (a) as required by federal securities law in connection with the filing of final Transaction Documents
with the Commission and (b) to the extent such disclosure is required by law or Trading Market or FINRA regulations, in which case
the Company shall provide the Purchaser with prior notice of such disclosure permitted under this clause (b).

4.5 
Shareholder Rights Plan. No claim will be made or enforced by the Company or, with the consent of the Company, any
other Person, that Purchaser is an “Acquiring Person” under any control share acquisition, business combination,
poison pill (including any distribution under a rights agreement) or similar anti-takeover plan or arrangement in effect or hereafter
adopted by the Company, or that Purchaser could be deemed to trigger the provisions of any such plan or arrangement, by virtue
of receiving Securities under the Transaction Documents or under any other agreement between the Company and the Purchaser, except
as otherwise required by law.

4.6 
Schedule 14C. The Company shall prepare and file, at the expense of the Company, with the SEC, as promptly as practicable
after the date hereof, but in no event later than ten (10) days after the date hereof, an information statement (the "Information
Statement"), substantially in the form that has been previously reviewed and reasonably approved by the Purchasers and
Loeb & Loeb LLP informing the stockholders of the Company of the receipt of the Stockholder Approval and the date

     -26-

     

    

the Information Statement is initially
effective (the “Stockholder Approval Date”). If an Information Statement is not effective by August 15, 2018,
the Company shall prepare and file, at the expense of the Company, with the SEC a preliminary proxy statement, substantially in
the form that has been previously reviewed and reasonably approved by the Purchasers and Loeb & Loeb LLP with respect to a
Stockholder Meeting, which shall be promptly called and held not later than September 15, 2018 (the “Stockholder Meeting
Deadline”) soliciting each such stockholder's affirmative vote for resolutions concerning the matters covered by the
Stockholder Approval (the “Stockholder Meeting Approval”), and the Company shall use its reasonable best efforts
to solicit its stockholders’ approval of such resolutions and to cause the Board of Directors of the Company to recommend
to the stockholders that they approve such resolutions. The Company shall be obligated to seek to obtain the Stockholder Meeting
Approval by the Stockholder Meeting Deadline. If, despite the Company’s reasonable best efforts the Stockholder Meeting Approval
is not obtained on or prior to the Stockholder Meeting Deadline, the Company shall cause an additional Stockholder Meeting to be
held on or prior to November 15, 2018. If, despite the Company’s reasonable best efforts the Stockholder Meeting Approval
is not obtained after such subsequent stockholder meetings, the Company shall cause an additional Stockholder Meeting to be held
semi-annually thereafter until such Stockholder Meeting Approval is obtained.

4.7 
 Use of Proceeds. Except as set forth on Schedule 4.7, the Company shall use the net proceeds from the sale
of the Securities hereunder for working capital purposes, including but not limited to research and development activities, and
shall not without Acuitas’ consent use such proceeds: (a) for the satisfaction of any portion of the Company’s debt
(other than payment of trade payables in the ordinary course of the Company’s business and prior practices), (b) for the
redemption of any shares of Common Stock or Common Stock Equivalents, (c) for the settlement of any outstanding litigation or (d)
in violation of FCPA or OFAC regulations.

4.8 
Indemnification of Purchaser. Subject to the provisions of this Section 4.8, the Company will indemnify and hold
each Purchaser and its directors, officers, shareholders, members, partners, employees and agents (and any other Persons with a
functionally equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title), each Person
who controls such Purchaser (within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the
directors, officers, shareholders, agents, members, partners or employees (and any other Persons with a functionally equivalent
role of a Person holding such titles notwithstanding a lack of such title or any other title) of such controlling persons (each,
a “Purchaser Party”) harmless from any and all losses, liabilities, obligations, claims, contingencies, damages,
costs and expenses, including all judgments, amounts paid in settlements, court costs and reasonable attorneys’ fees and
costs of investigation that any Purchaser Party may suffer or incur as a result of or relating to (a) any breach of any of the
representations, warranties, covenants or agreements made by the Company in this Agreement or in the other Transaction Documents
or (b) any action instituted against the Purchaser Parties in any capacity, or any of them or their respective Affiliates, by any
shareholder of the Company who is not an Affiliate of such Purchaser

     -27-

     

    

Party, with respect to any of the
transactions contemplated by the Transaction Documents (unless such action is based upon a breach of such Purchaser Party’s
representations, warranties or covenants under the Transaction Documents or any agreements or understandings such Purchaser Party
may have with any such shareholder or any violations by such Purchaser Party of state or federal securities laws or any conduct
by such Purchaser Party which constitutes fraud, gross negligence, willful misconduct or malfeasance). If any action shall be brought
against a Purchaser Party in respect of which indemnity may be sought pursuant to this Agreement, such Purchaser Party shall promptly
notify the Company in writing, and the Company shall have the right to assume the defense thereof with counsel of its own choosing
reasonably acceptable to the Purchaser Party. Any Purchaser Party shall have the right to employ separate counsel in any such action
and participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense of such Purchaser Party
except to the extent that (i) the employment thereof has been specifically authorized by the Company in writing, (ii) the Company
has failed after a reasonable period of time to assume such defense and to employ counsel or (iii) in such action there is, in
the reasonable opinion of counsel, a material conflict on any material issue between the position of the Company and the position
of such Purchaser Party, in which case the Company shall be responsible for the reasonable fees and expenses of no more than one
such separate counsel. The Company will not be liable to Purchaser Party under this Agreement (y) for any settlement by a Purchaser
Party effected without the Company’s prior written consent, which shall not be unreasonably withheld or delayed; or (z) to
the extent, but only to the extent that a loss, claim, damage or liability is attributable to Purchaser Party’s breach of
any of the representations, warranties, covenants or agreements made by such Purchaser Party in this Agreement or in the other
Transaction Documents. The indemnification required by this Section 4.8 shall be made by periodic payments of the amount thereof
during the course of the investigation or defense, as and when bills are received or are incurred. The indemnity agreements contained
herein shall be in addition to any cause of action or similar right of Purchaser Party against the Company or others and any liabilities
the Company may be subject to pursuant to law.

4.9 
Reservation of Common Stock. Following the Shareholder Approval and Amendment to Articles, the Company shall have
reserved and the Company shall continue to reserve and keep available at all times, free of preemptive rights, a sufficient number
of shares of Common Stock for the purpose of enabling the Company to issue the Shares pursuant to this Agreement, the conversion
of the Preferred Shares and the Warrant Shares pursuant to any exercise of the Warrants.

4.10   
Trading of Common Stock. The Company will take all action reasonably necessary to continue the listing and trading
of its Common Stock on a Trading Market and will comply in all respects with the Company’s reporting, filing and other obligations
under the bylaws or rules of the Trading Market. The Company agrees to maintain the eligibility of the Common Stock for electronic
transfer through the Depository Trust Company or another established clearing corporation, including, without limitation, by timely
payment of fees to the Depository Trust Company or such other established clearing corporation in connection with such electronic
transfer.

     -28-

     

    

4.11   
Future Purchase Rights. In the event the Company has not received funding grants (which grants shall not involve
the issuance of any Common Stock Equivalents) of at least $3,000,000 (the “Required Funds”) by the one year
anniversary of the Closing Date (the “Funding Date”), Acuitas shall be entitled to purchase additional shares
of Common Stock at the then effective Per Share Purchase Price, together with Warrants to purchase an equal number of shares of
Common Stock at the then effective Exercise Price (as defined in the Warrants). Such aggregate purchase price shall be not greater
than the difference between (x) the Required Funds and (y) the actual amount of funding grants (which grants shall not involve
the issuance of any Common Stock Equivalents) received by the Funding Date (the “Required Additional Amount”).
Acuitas’ right under this Section 4.11 shall be exercisable by Acuitas, in its sole discretion, during the two week period
following the Funding Date.

4.12   
Subsequent Equity Sales. From the date hereof until one hundred eighty (180) days after the Closing Date, neither
the Company nor any Subsidiary shall issue, enter into any agreement to issue or announce the issuance or proposed issuance of,
any Common Stock or Common Stock Equivalents. Notwithstanding the foregoing, this Section 4.12 shall not apply in respect of an
Exempt Issuance, except that no Variable Rate Transaction shall be an Exempt Issuance. “Variable Rate Transaction”
means a transaction in which the Company (i) issues or sells any debt or equity securities that are convertible into, exchangeable
or exercisable for, or include the right to receive additional shares of Common Stock either (A) at a conversion price, exercise
price or exchange rate or other price that is based upon and/or varies with the trading prices of or quotations for the Common
Stock at any time after the initial issuance of such debt or equity securities, or (B) with a conversion, exercise or exchange
price that is subject to being reset at some future date after the initial issuance of such debt or equity security or upon the
occurrence of specified or contingent events directly or indirectly related to the business of the Company or the market for the
Common Stock or (ii) enters into, or effects a transaction under, any agreement, including, but not limited to, an equity line
of credit, whereby the Company may issue securities at a future determined price. Acuitas shall be entitled to obtain injunctive
relief against the Company to preclude any such issuance, which remedy shall be in addition to any right to collect damages.

4.13   
Certain Transactions and Confidentiality. Each Purchaser covenants that neither it nor any Affiliate acting on its
behalf or pursuant to any understanding with it will execute any purchases or sales, including Short Sales of any of the Company’s
securities during the period commencing with the execution of this Agreement and ending at such time that the transactions contemplated
by this Agreement are first publicly announced pursuant to the Form 8-K described in Section 4.4. 
Each Purchaser covenants that until such time as the transactions contemplated by this Agreement are publicly disclosed
by the Company pursuant to the Form 8-K as described in Section 4.4, Purchaser will maintain the confidentiality of the existence
and terms of this transaction and the information included in the Disclosure Schedules.  Acuitas acknowledges
that in connection with the appointment of Mr. Peizer pursuant to Section 2.2(a)(vii), Acuitas will be subject to certain obligations
of confidentiality, as more fully described in Schedule 4.13.

     -29-

     

    

4.14   
Capital Changes. Until the one (1) year anniversary of the Closing Date, the Company shall not undertake a reverse
or forward share split or reclassification of the Common Stock without the prior written consent of the Purchaser.

4.15   
Exercise Procedures. The form of Notice of Exercise included in the Warrants set forth the totality of the procedures
required of the Purchasers in order to exercise such Warrants. No additional legal opinion, other information or instructions shall
be required of the Purchasers to exercise their Warrants. Without limiting the preceding sentences, no ink original Notice of Exercise
shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise form
be required in order to exercise the Warrants. The Company shall honor exercises of the Warrants and shall deliver Warrant Shares
in accordance with the terms, conditions and time periods set forth in the Transaction Document.

4.16   
Form D; Blue Sky Filings. The Company agrees to timely file a Form D with respect to the Preferred Shares, the Shares,
Warrants and Warrant Shares as required under Regulation D and to provide a copy thereof, promptly upon request of Purchaser. The
Company shall take such action as the Company shall reasonably determine is necessary in order to obtain an exemption for, or to
qualify the Shares, Warrants and Warrant Shares for, sale to the Purchasers at the Closing under applicable securities or “Blue
Sky” laws of the states of the United States, and shall provide evidence of such actions promptly upon request of Purchasers.

ARTICLE V.

MISCELLANEOUS

5.1 
Termination.  This Agreement may be terminated by Acuitas on behalf of all Purchasers by written notice to the
Company, if the Closing has not been consummated on or before July 6, 2018; provided, however, that no such termination
will affect the right of any party to sue for any breach by any other party (or parties).

5.2 
Fees and Expenses. Except as expressly set forth in the Transaction Documents to the contrary, each party shall pay
the fees and expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such
party incident to the negotiation, preparation, execution, delivery and performance of this Agreement. The Company shall pay all
Transfer Agent fees (including, without limitation, any fees required for same-day processing of any instruction letter delivered
by the Company and any exercise notice delivered by a Purchaser), stamp taxes and other taxes and duties levied in connection with
the delivery of any Securities to the Purchasers.

5.3 
Entire Agreement. The Transaction Documents, together with the exhibits and schedules thereto, contain the entire
understanding of the parties with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings,
oral or written, with respect to such matters, which the parties acknowledge have been merged into such documents, exhibits and
schedules.

     -30-

     

    

5.4 
Notices. Any and all notices or other communications or deliveries required or permitted to be provided hereunder
shall be in writing and shall be deemed given and effective on the earliest of: (a) the date of transmission, if such notice or
communication is delivered via facsimile at the facsimile number or email attachment at the email address as set forth on the signature
pages attached hereto at or prior to 5:30 p.m. (New York City time) on a Trading Day, (b) the next Trading Day after the date of
transmission, if such notice or communication is delivered via facsimile at the facsimile number or email attachment at the email
address as set forth on the signature pages attached hereto on a day that is not a Trading Day or later than 5:30 p.m. (New York
City time) on any Trading Day, (c) the second (2nd) Trading Day following the date of mailing, if sent by U.S. nationally
recognized overnight courier service or (d) upon actual receipt by the party to whom such notice is required to be given. The address
for such notices and communications shall be as set forth on the signature pages attached hereto. To the extent that any notice
provided pursuant to any Transaction Document constitutes, or contains, material, non-public information regarding the Company
or any Subsidiaries, the Company shall reasonably promptly file such notice with the Commission pursuant to a Current Report on
Form 8-K.

5.5 
Amendments; Waivers. No provision of this Agreement may be waived, modified, supplemented or amended except in a
written instrument signed, in the case of an amendment, by the Company and the Purchasers or, in the case of a waiver, by the party
against whom enforcement of any such waived provision is sought. No waiver of any default with respect to any provision, condition
or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default
or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of any party to exercise any
right hereunder in any manner impair the exercise of any such right. Any amendment effected in accordance with this Section 5.5
shall be binding upon the Purchasers and subsequent holders of Securities and the Company.

5.6 
Headings. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not
be deemed to limit or affect any of the provisions hereof.

5.7 
Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their successors
and permitted assigns. The Company may not assign this Agreement or any rights or obligations hereunder without the prior written
consent of the Purchasers (other than by merger). Each Purchaser may assign any or all of its rights under this Agreement to any
Person to whom such Purchaser assigns or transfers any Securities, provided that such transferee agrees in writing to be bound,
with respect to the transferred Securities, by the provisions of the Transaction Documents that apply to a “Purchaser.”

5.8 
Third-Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective
successors and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person,
except as otherwise set forth in Section 4.8, this Section 5.8.

     -31-

     

    

5.9 
Governing Law. All questions concerning the construction, validity, enforcement and interpretation of the Transaction
Documents shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without
regard to the principles of conflicts of law thereof. Each party agrees that all legal Proceedings concerning the interpretations,
enforcement and defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought
against a party hereto or its respective affiliates, directors, officers, shareholders, partners, members, employees or agents)
shall be commenced exclusively in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits
to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication
of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including with
respect to the enforcement of any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert in any
Action or Proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such Action or Proceeding
is improper or is an inconvenient venue for such Proceeding. Each party hereby irrevocably waives personal service of process and
consents to process being served in any such Action or Proceeding by mailing a copy thereof via registered or certified mail or
overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and
agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall
be deemed to limit in any way any right to serve process in any other manner permitted by law. If any party shall commence an Action
or Proceeding to enforce any provisions of the Transaction Documents, then, in addition to the obligations of the Company under
Section 4.8, the prevailing party in such Action or Proceeding shall be reimbursed by the non-prevailing party for its reasonable
attorneys’ fees and other costs and expenses incurred with the investigation, preparation and prosecution of such Action
or Proceeding.

5.10   
Survival. The representations and warranties contained herein shall survive the Closing and the delivery of the Securities.

5.11   
Execution. This Agreement may be executed in two or more counterparts, all of which when taken together shall be
considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered
to each other party, it being understood that the parties need not sign the same counterpart. In the event that any signature is
delivered by facsimile transmission or by e-mail delivery of a “.pdf” format data file, such signature shall create
a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect
as if such facsimile or “.pdf” signature page were an original thereof.

5.12   
Severability. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction
to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein
shall remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use
their commercially reasonable

     -32-

     

    

efforts to find and employ an alternative
means to achieve the same or substantially the same result as that contemplated by such term, provision, covenant or restriction.
It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining terms, provisions,
covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or unenforceable.

5.13   
Rescission and Withdrawal Right. Notwithstanding anything to the contrary contained in (and without limiting any
similar provisions of) any of the other Transaction Documents, whenever a Purchaser exercises a right, election, demand or option
under a Transaction Document and the Company does not timely perform its related obligations within the periods therein provided,
then such Purchaser may rescind or withdraw, in its sole discretion from time to time upon written notice to the Company, any relevant
notice, demand or election in whole or in part without prejudice to its future actions and rights; provided, however, that
in the case of a rescission of an exercise of a Warrant, such Purchaser shall be required to return any shares of Common Stock
subject to any such rescinded exercise notice concurrently with the return to such Purchaser of the aggregate exercise price paid
to the Company for such shares and the restoration of such Purchaser’s right to acquire such shares pursuant to such Purchaser’s
Warrant (including, issuance of a replacement warrant certificate evidencing such restored right).

5.14   
Replacement of Securities. If any certificate or instrument evidencing any Securities is mutilated, lost, stolen
or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in
the case of mutilation), or in lieu of and substitution therefor, a new certificate or instrument, but only upon receipt of evidence
reasonably satisfactory to the Company of such loss, theft or destruction. The applicant for a new certificate or instrument under
such circumstances shall also pay any reasonable third-party costs (including customary indemnity) associated with the issuance
of such replacement Securities.

5.15   
Remedies. In addition to being entitled to exercise all rights provided herein or granted by law, including recovery
of damages, each of the Purchasers and the Company will be entitled to specific performance under the Transaction Documents. The
parties agree that monetary damages may not be adequate compensation for any loss incurred by reason of any breach of obligations
contained in the Transaction Documents and hereby agree to waive and not to assert in any Action for specific performance of any
such obligation the defense that a remedy at law would be adequate.

5.16   
Payment Set Aside. To the extent that the Company makes a payment or payments to a Purchaser pursuant to any Transaction
Document or a Purchaser enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement
or exercise or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from,
disgorged by or are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other Person
under any law (including, without limitation, any bankruptcy law, state or federal law, common law or equitable cause of action),
then to the extent of any such

     -33-

     

    

restoration the obligation or part
thereof originally intended to be satisfied shall be revived and continued in full force and effect as if such payment had not
been made or such enforcement or setoff had not occurred.

5.17   
Payment Obligations. The Company’s obligations to pay any partial liquidated damages or other amounts owing
under the Transaction Documents is a continuing obligation of the Company and shall not terminate until all unpaid partial liquidated
damages and other amounts have been paid notwithstanding the fact that the instrument or security pursuant to which such partial
liquidated damages or other amounts are due and payable shall have been canceled.

5.18   
Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of
any right required or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised
on the next succeeding Business Day.

5.19   
Construction. The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity
to revise the Transaction Documents and, therefore, the normal rule of construction to the effect that any ambiguities are to be
resolved against the drafting party shall not be employed in the interpretation of the Transaction Documents or any amendments
thereto. In addition, each and every reference to share prices, Preferred Stock and Common Stock in any Transaction Document shall
be subject to adjustment for reverse and forward share splits, share dividends, share combinations and other similar transactions
of the Common Stock that occur after the date of this Agreement.

5.20   
WAIVER OF JURY TRIAL. IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY
OTHER PARTY, THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY,
UNCONDITIONALLY, IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY. 

 

(Signature Pages Follow)

     -34-

     

    

IN WITNESS WHEREOF,
the parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories
as of the date first indicated above.

 

	BIOVIE INC.	Address for Notice:
	 	 
	
        By:__ /s/ Jonathan Adams _______________________

        Name: Jonathan Adams

        Title: Chief Executive Officer

         
	
         

        E-Mail:

        Fax:

	
        With a copy to (which shall not constitute notice):

         

         

         

         

         
	 
	ACUITAS GROUP HOLDINGS, LLC	Address for Notice:
	 	 
	
        By:__/s/ Terren S. Peizer__________________________

        Name: Terren S. Peizer

        Title: Managing Member

         
	
        11601 Wilshire Boulevard

        Suite 1100

        Los Angeles, CA 90025

        E-Mail:

        Fax:

	
        With a copy to (which shall not constitute notice):

         

        Mitchell S. Nussbaum

        Loeb & Loeb LLP

        345 Park Avenue

        New York, NY 10154

         

         

         
	 

 

 

Investment Amount: $3,000,000.00 

 

     -35-

     

    

 

 

	Cuong Do	Address for Notice:
	 	 
	
        By:_/s/ Cuong Do_______________________________

        Name: Cuong Do

         
	
        Address:

        Do & Rickles Investments, LLC

        5 India Brook Drive, Menaham, NJ 07945

        E-Mail:

        Fax:

	
        With a copy to (which shall not constitute notice):

         

         

         

         
	 

 

 

Investment Amount: $130,000.00

 

 

 

 

     -36-

     

    

 

 

	Jim Lang	Address for Notice:
	 	 
	
        By:__/s/ Jim Lang_______________________________

        Name: Jim Lang

         
	
        Address:

        E-Mail:

        Fax:

	
        With a copy to (which shall not constitute notice):

         

         

         

         
	 

Investment Amount: $30,000.00

 

 

 

 

     -37-

     

    

 

 

	Jonathan Adams	Address for Notice:
	 	 
	
        By:_/s/ Jonathan Adams__________________________

        Name: Jonathan Adams

         
	
        Address:

        E-Mail:

        Fax:

	
        With a copy to (which shall not constitute notice):

         

         

         

         
	 

Investment Amount: $15,000.00

 

 

 

 

     -38-

     

    

 

	Michael Sherman	Address for Notice:
	 	 
	
        By:__/s/ Michael Sherman_____________________

        Name: Michael Sherman

         
	
        Address:

        E-Mail:

        Fax:

	
        With a copy to (which shall not constitute notice):

         

         

         

         
	 

Investment Amount: $25,000.00

 

     -39-

     

    

 Exhibit A

 

Form of Warrant

 

 

 

 

 

 

 

 

 

 

    

     

    
THIS WARRANT AND THE COMMON SHARES
ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES
LAWS. THIS WARRANT AND THE COMMON SHARES ISSUABLE UPON EXERCISE OF THIS WARRANT MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED
IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO THIS WARRANT UNDER SAID ACT AND ANY APPLICABLE STATE SECURITIES LAWS
OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO BIOVIE INC. THAT SUCH REGISTRATION IS NOT REQUIRED.

Right to Purchase up to [___________]
Shares of Common Stock of

BioVie Inc.

(subject to adjustment as provided herein)

COMMON STOCK PURCHASE WARRANT

No. B-[___]Issue Date: [___], 2018

BIOVIE
INC., a Nevada corporation (the “Company”), hereby certifies that, for value received, [________], or assigns
(the “Holder”), is entitled, subject to the terms set forth below, to purchase from the Company (as defined herein)
from and after the Issue Date of this Warrant and at any time, up to [______] fully paid and nonassessable shares of Common Stock
(as hereinafter defined), par value of $0.0001 per share, at the applicable Exercise Price per share (as defined below). The number
and character of such shares of Common Stock and the applicable Exercise Price per share are subject to adjustment as provided
herein.

This Warrant has
been issued pursuant to the terms of that certain Securities Purchase Agreement, dated as of July 3, 2018 (the “Purchase
Agreement”), by and among the Company and Holder and the other Purchasers party thereto. Capitalized terms not defined herein
shall have the meanings given to them in the Purchase Agreement. As used herein the following terms, unless the context otherwise
requires, have the following respective meanings:

(a)              
“Aggregate Exercise Price” means an amount equal to the product of (i) the number of shares of Common Stock
in respect of which this Warrant is being exercised pursuant to Section 2 hereof, multiplied by (ii) the then-current Exercise
Price.

(b)              
“Business Day” means any day, except a Saturday, Sunday or legal holiday, on which banking institutions in the
city of New York, New York are authorized or obligated by law or executive order to close.

(c)              
The term “Company” shall mean BioVie Inc. and any person or entity which shall succeed, or assume the obligations
of, BioVie Inc. hereunder.

(d)              
The term “Common Stock” shall mean (i) the Company’s common shares, $0.001 par value per share; and (ii)
any other securities into which or for which any of the

     -1-

     

    

securities described in the preceding
clause (i) may be converted or exchanged pursuant to a plan of recapitalization, reorganization, merger, sale of assets or otherwise.

(e)              
The term “Exercise Price” shall mean an amount equal to one hundred twenty percent (120%) of the Per Share Purchase
Price under the Purchase Agreement, subject to adjustments as provided herein and therein.

(f)               
The term “Other Securities” shall mean any stock (other than Common Stock) and other securities of the Company
or any other person (corporate or otherwise) which the holder of the Warrant at any time shall be entitled to receive, or shall
have received, on the exercise of the Warrant, in lieu of or in addition to Common Stock, or which at any time shall be issuable
or shall have been issued in exchange for or in replacement of Common Stock or Other Securities pursuant to Section 4 or otherwise.

(g)              
“Trading Day” means a day on which the principal Trading Market is open for trading.

(h)              
“Trading Market” means any of the following markets or exchanges on which the Common Stock is listed or quoted
for trading on the date in question: the NYSE MKT, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select
Market, the New York Stock Exchange, the OTCQB or OTCQX (or any successors to any of the foregoing).

1.                 
Term of Warrant. Subject to the terms and conditions hereof, at any time or from time to time after the date hereof
and prior to 5:00 p.m., New York time, on the sixth (6th) anniversary of the date hereof or, if such day is not a Business Day,
on the next preceding Business Day (the “Exercise Period”) the Holder of this Warrant may exercise this Warrant in
whole or in part, of the Common Stock purchasable upon exercise hereof (subject to adjustment as provided herein).

2.                 
Exercise of Warrant.

2.1             
Number of Shares Issuable upon Exercise. From and after the date hereof, the Holder shall be entitled to receive,
upon exercise of this Warrant in whole or in part, upon surrender of this Warrant to the Company at its principal executive office
(or an indemnification undertaking with respect to this Warrant in the case of loss, theft, or destruction), or by delivery of
an original or fax copy of an exercise notice in the form attached hereto as Exhibit A (the “Exercise Notice”), duly
completed, and payment to the Company of the Aggregate Exercise Price, the Holder shall be entitled to receive, shares of Common
Stock of the Company, subject to adjustment pursuant to Section 5.

2.2             
Fair Market Value. For purposes hereof, the “Fair Market Value” of a share of Common Stock as of a particular
date (the “Determination Date”) shall mean:

(a)              
If the Company’s Common Stock is traded on a national exchange, then the closing or last sale price, respectively,
reported for the last Business Day immediately preceding the Determination Date.

     -2-

     

    

(b)              
If the Company’s Common Stock is not traded on a national exchange but is traded on the OTCQX or OTCQB, then the mean
of the average of the closing bid and asked prices reported for the last Business Day immediately preceding the Determination Date.

(c)              
Except as provided in clause (d) below, if the Company’s Common Stock is not publicly traded, then as the Holder and
the Board of Directors of the Company jointly agree or in the absence of agreement by arbitration in accordance with the rules
then in effect of the American Arbitration Association, before a single arbitrator to be chosen from a panel of persons qualified
by education and training to pass on the matter to be decided.

(d)              
If the Determination Date is the date of a liquidation, dissolution or winding up, or any event deemed to be a liquidation,
dissolution or winding up pursuant to the Company’s charter, then all amounts to be payable per share to holders of the Common
Stock pursuant to the charter in the event of such liquidation, dissolution or winding up, plus all other amounts to be payable
per share in respect of the Common Stock in liquidation under the charter, assuming for the purposes of this clause (d) that all
of the shares of Common Stock then issuable upon exercise of the Warrant are outstanding at the Determination Date.

2.3             
Company Acknowledgment. The Company will, at the time of the exercise of this Warrant, upon the request of the Holder
acknowledge in writing its continuing obligation to afford to such Holder any rights to which such Holder shall continue to be
entitled after such exercise in accordance with the provisions of this Warrant. If the Holder shall fail to make any such request,
such failure shall not affect the continuing obligation of the Company to afford to such Holder any such rights.

2.4             
Trustee for Warrant Holders. In the event that a bank or trust company shall have been appointed as trustee for the
holders of this Warrant pursuant to Subsection 3.2, such bank or trust company shall have all the powers and duties of a warrant
agent (as hereinafter described) and shall accept, in its own name for the account of the Company or such successor person as may
be entitled thereto, all amounts otherwise payable to the Company or such successor, as the case may be, on exercise of this Warrant
pursuant to this Section 1.

3.                 
Procedure for Exercise.

3.1             
Delivery of Stock Certificates, Etc., on Exercise. The Company agrees that the shares of Common Stock purchased upon
exercise of this Warrant shall be deemed to be issued to the Holder as the record owner of such shares as of the close of business
on the date on which this Warrant shall have been surrendered and payment made for such shares in accordance herewith. Not later
than two (2) Trading Days after such date (the “Share Delivery Date”), the Company shall deliver, or cause to
be delivered, to the holder (A) a certificate or certificates representing the shares of Common Stock purchased upon exercise of
this Warrant which, on or after the six month anniversary of the Issue Date, provided the Holder is not an Affiliate, shall be
free of restrictive legends and trading restrictions representing the number of shares of Common Stock purchased upon exercise
of this Warrant. On or after the six month anniversary of the

     -3-

     

    

Issue Date, provided the Holder is not
an Affiliate, the Company shall use its best efforts to deliver any certificate or certificates required to be delivered by the
Company under this Section 3.1 electronically through the Depository Trust Company or another established clearing corporation
performing similar functions.

3.2             
Failure to Deliver Certificates. If, in the case of any Exercise Notice, such certificate or certificates are not
delivered to or as directed by the applicable holder by the Share Delivery Date, the holder shall be entitled to elect by written
notice to the Company at any time on or before its receipt of such certificate or certificates, to rescind such Exercise Notice,
in which event the Company shall promptly return to the holder any original Warrant delivered to the Company and the holder shall
promptly return to the Company the Common Stock certificates issued to such holder pursuant to the rescinded Exercise Notice.

3.3             
Obligation Absolute; Partial Liquidated Damages. The Company’s obligations to issue and deliver the shares
of Common Stock purchased upon exercise of this Warrant upon exercise of this Warrant in accordance with the terms hereof are absolute
and unconditional, irrespective of any action or inaction by the holder to enforce the same, any waiver or consent with respect
to any provision hereof, the recovery of any judgment against any person or any action to enforce the same, or any setoff, counterclaim,
recoupment, limitation or termination, or any breach or alleged breach by the holder or any other person of any obligation to the
Company or any violation or alleged violation of law by the holder or any other person, and irrespective of any other circumstance
which might otherwise limit such obligation of the Company to the Holder in connection with the issuance of such shares of Common
Stock purchased upon exercise of this Warrant; provided, however, that such delivery shall not operate as a waiver
by the Company of any such action the Company may have against the holder. In the event the holder of this Warrant shall elect
to exercise any or all portion hereof, the Company may not refuse exercise based on any claim that the holder or anyone associated
or affiliated with the holder has been engaged in any violation of law, agreement or for any other reason, unless an injunction
from a court, on notice to holder, restraining and or enjoining exercise of all or part of this Warrant shall have been sought
and obtained, and the Company posts a surety bond for the benefit of the holder in the amount of 150% of the value of the shares
of Common Stock to be purchased upon exercise of this Warrant, which is subject to the injunction, which bond shall remain in effect
until the completion of arbitration/litigation of the underlying dispute and the proceeds of which shall be payable to the holder
to the extent it obtains judgment. In the absence of such injunction, the Company shall issue the shares of Common Stock purchased
upon exercise of this Warrant, upon a properly noticed exercise. If the Company fails for any reason to deliver to the holder such
certificate or certificates pursuant to Section 3.1 by the Share Delivery Date, the Company shall pay to the holder, in cash, as
liquidated damages and not as a penalty, for each $1,000 of Fair Market Value of the shares of Common Stock to be purchased upon
exercise of this Warrant, $10 per Trading Day (increasing to $20 per Trading Day on the fifth (5th) Trading Day after
such liquidated damages begin to accrue) for each Trading Day after such Share Delivery Date until such certificates are delivered
or holder rescinds such exercise. Nothing herein shall limit a holder’s right to pursue actual damages for the Company’s
failure to deliver the shares of Common Stock purchased upon exercise of this Warrant within the period specified herein and the
holder shall have the right to pursue all remedies available to it hereunder, at law or in equity including, without limitation,
a decree of specific performance

     -4-

     

    

and/or injunctive relief. The exercise
of any such rights shall not prohibit the holder from seeking to enforce damages pursuant to any other Section hereof or under
applicable law.

3.4             
Compensation for Buy-In on Failure to Timely Deliver Certificates Upon Exercise. In addition to any other rights
available to the holder, if the Company fails for any reason to deliver to the holder such certificate or certificates by the Share
Delivery Date pursuant to Section 3.1, and if after such Share Delivery Date the holder is required by its brokerage firm to purchase
(in an open market transaction or otherwise), or the holder’s brokerage firm otherwise purchases, shares of Common Stock
to deliver in satisfaction of a sale by the holder of the shares of Common Stock purchased upon exercise of this Warrant which
the Holder was entitled to receive upon the exercise relating to such Share Delivery Date (a “Buy-In”), then
the Company shall (A) pay in cash to the holder (in addition to any other remedies available to or elected by the holder) the amount,
if any, by which (x) the holder’s total purchase price (including any brokerage commissions) for the Common Stock so purchased
exceeds (y) the product of (1) the aggregate number of shares of Common Stock that the Holder was entitled to receive from the
exercise at issue multiplied by (2) the actual sale price at which the sell order giving rise to such purchase obligation was executed
(including any brokerage commissions) and (B) at the option of the holder, either reissue (if surrendered) this Warrant representing
that number of shares of Common Stock which it represented prior to such exercise (in which case such exercise shall be deemed
rescinded) or deliver to the holder the number of shares of Common Stock that would have been issued if the Company had timely
complied with its delivery requirements under Section 3.1. For example, if the holder purchases Common Stock having a total purchase
price of $11,000 to cover a Buy-In with respect to an attempted exercise of this Warrant with respect to which the actual sale
price of the shares of Common Stock purchased upon exercise of this Warrant (including any brokerage commissions) giving rise to
such purchase obligation was a total of $10,000 under clause (A) of the immediately preceding sentence, the Company shall be required
to pay the holder $1,000. The holder shall provide the Company written notice indicating the amounts payable to the holder in respect
of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a holder’s
right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific
performance and/or injunctive relief with respect to the Company’s failure to timely deliver certificates representing shares
of Common Stock upon exercise of this Warrant as required pursuant to the terms hereof.

3.5             
Exercise.

(a)              
Payment may be made in cash by wire transfer of immediately available funds to an account designated in writing by the Company,
or by certified or official bank check payable to the order of the Company equal to the Aggregate Exercise Price for the number
of Common Shares specified in such Exercise Notice (as such exercise number shall be adjusted to reflect any adjustment in the
total number of shares of Common Stock issuable to the Holder per the terms of this Warrant) and the Holder shall thereupon be
entitled to receive the number of duly authorized, validly issued, fully-paid and non-assessable shares of Common Stock (or Other
Securities) determined as provided herein.

(b)              
Notwithstanding the provisions of subsection (a) above to the contrary, if at the time the Holder exercises this Warrant
a registration statement covering the

     -5-

     

    

Common Stock issuable to the Holder
upon exercise of this Warrant shall not be effective under the Securities Act (as hereafter defined) in respect of such Common
Stock, payment may be made, in the Holder’s discretion, either (i) in cash by wire transfer of immediately available funds
to an account designated in writing by the Company or by certified or official bank check payable to the order of the Company equal
to the applicable Aggregate Exercise Price, (ii) by delivery of this Warrant, or shares of Common Stock and/or Common Stock receivable
upon exercise of this Warrant in accordance with the formula set forth in subsection (c) below, or (iii) by a combination of any
of the foregoing methods, for the number of Common Shares specified in such Exercise Notice (as such exercise number shall be adjusted
to reflect any adjustment in the total number of shares of Common Stock issuable to the Holder per the terms of this Warrant) and
the Holder shall thereupon be entitled to receive the number of duly authorized, validly issued, fully-paid and non-assessable
shares of Common Stock (or Other Securities) determined as provided herein.

(c)              
In accordance with subsection (b) above, if the Fair Market Value of one share of Common Stock is greater than the Exercise
Price (at the date of calculation as set forth below), in lieu of exercising this Warrant for cash, the Holder may elect to receive
shares equal to the value (as determined below) of this Warrant (or the portion thereof being exercised) by surrender of this Warrant
at the principal office of the Company together with the properly endorsed Exercise Notice in which event the Company shall issue
to the Holder a number of shares of Common Stock computed using the following formula:

		X=	_Y(A-B)_

A

Where X =the
number of shares of Common Stock to be issued to the Holder

		Y =	the number of shares of Common Stock purchasable under this Warrant or, if only a portion of this
Warrant is being exercised, the portion of this Warrant being exercised (at the date of such calculation)

		A =	the Fair Market Value of one share of the Company’s Common Stock (at the date of such calculation)

		B =	the Exercise Price per share (as adjusted to the date of such calculation)

4.                 
Effect of Reorganization, Etc.; Adjustment of Exercise Price.

4.1             
Reorganization, Consolidation, Merger, Etc. In case at any time or from time to time the Company shall (a) effect
a reorganization, (b) consolidate with or merge into any other person, or (c) transfer all or substantially all of its properties
or assets to any other person under any plan or arrangement contemplating the dissolution of the Company, then, in each such case,
as a condition to the consummation of such a transaction, proper and adequate provision shall be made by the Company whereby the
Holder, on the exercise hereof as provided in Section 1 at any time after the consummation of such reorganization, consolidation
or merger or the effective date of such dissolution, as the case may be, upon closing date of any such

     -6-

     

    

reorganization, consolidation, merger
or sale or transfer of assets, shall receive, in lieu of the Common Stock (or Other Securities) issuable on such exercise prior
to such consummation or such effective date, the stock and other securities and property (including cash) to which such Holder
would have been entitled upon such consummation or in connection with such dissolution, as the case may be, if such Holder had
so exercised this Warrant, immediately prior thereto, all subject to further adjustment thereafter as provided in Section 5.

4.2             
Dissolution. In the event of any dissolution of the Company following the transfer of all or substantially all of
its properties or assets, the Company, concurrently with any distributions made to holders of its Common Stock, shall at its expense
deliver or cause to be delivered to the Holder the stock and other securities and property (including cash, where applicable) receivable
by the Holder pursuant to Section 4.1, or, if the Holder shall so instruct the Company, to a bank or trust company specified by
the Holder and having its principal office in New York, NY as trustee for the Holder (the “Trustee”).

4.3             
Continuation of Terms. Upon any reorganization, consolidation, merger or transfer (and any dissolution following
any transfer) referred to in this Section 4, this Warrant shall continue in full force and effect and the terms hereof shall be
applicable to the shares of stock and other securities and property receivable on the exercise of this Warrant after the consummation
of such reorganization, consolidation or merger or the effective date of dissolution following any such transfer, as the case may
be, and shall be binding upon the issuer of any such stock or other securities, including, in the case of any such transfer, the
person acquiring all or substantially all of the properties or assets of the Company, whether or not such person shall have expressly
assumed the terms of this Warrant as provided in Section 5. In the event this Warrant does not continue in full force and effect
after the consummation of the transactions described in this Section 4, then the Company’s securities and property (including
cash, where applicable) receivable by the Holder will be delivered to the Holder or the Trustee as contemplated by Section 4.2.

5.                 
Extraordinary Events Regarding Common Stock. In the event that the Company shall (a) issue additional shares of the
Common Stock as a dividend or other distribution on outstanding Common Stock or any preferred stock issued by the Company, (b)
subdivide its outstanding shares of Common Stock, or (c) combine its outstanding shares of the Common Stock into a smaller number
of shares of the Common Stock, then, in each such event, the Exercise Price shall, simultaneously with the happening of such event,
be adjusted by multiplying the then Exercise Price by a fraction, the numerator of which shall be the number of shares of Common
Stock outstanding immediately prior to such event and the denominator of which shall be the number of shares of Common Stock outstanding
immediately after such event, and the product so obtained shall thereafter be the Exercise Price then in effect. The Exercise Price,
as so adjusted, shall be readjusted in the same manner upon the happening of any successive event or events described herein in
this Section 5. The number of shares of Common Stock that the Holder shall thereafter, on the exercise hereof as provided in Section
2, be entitled to receive shall be adjusted to a number determined by multiplying the number of shares of Common Stock that would
otherwise (but for the provisions of this Section 5) be issuable on such exercise by a fraction of which (a) the numerator is the
Exercise Price that would otherwise (but for the provisions of this Section 4) be in effect, and (b) the denominator is the Exercise
Price in effect on the date of such exercise (taking into account the provisions of this Section 5).

     -7-

     

    

Notwithstanding the foregoing, in no
event shall the Exercise Price be less than the par value of the Common Stock.

6.                 
Subsequent Equity Sales. If the Company, at any time while this Warrant is outstanding, shall issue shares of Common
Stock or securities or rights convertible or exchangeable into shares of Common Stock (“Common Stock Equivalents”)
entitling any person to acquire shares of Common Stock, at a price per share less than the then current Exercise Price (such issuances,
collectively, a “Dilutive Issuance”) (if the holder of the Common Stock or Common Stock Equivalents so issued shall
at any time, whether by operation of purchase price adjustments, reset provisions, floating conversion, exercise or exchange prices
or otherwise, or due to warrants, options or rights issued in connection with such issuance, be entitled to receive shares of Common
Stock at a price less than the Exercise Price, such issuance shall be deemed to have occurred for less than the Exercise Price),
then, the Exercise Price shall be reduced to such lower price per share. Such adjustment shall be made whenever such Common Stock
or Common Stock Equivalents are issued. Notwithstanding the foregoing, no adjustment will be made under this Section 6 in respect
of an Exempt Issuance. If the Company enters into a Variable Rate Transaction, despite the prohibition set forth in the Purchase
Agreement, the Company shall be deemed to have issued Common Stock or Common Stock Equivalents at the lowest possible conversion
price at which such securities may be converted or exercised. The Company shall notify the holder in writing, no later than the
third trading day following the issuance of any Common Stock or Common Stock Equivalent subject to this section, indicating therein
the applicable issuance price, or applicable reset price, exchange price, conversion price and other pricing terms.

For purposes of
this Section 6, the following subsections (1) to (5) shall also be applicable, other than in the case of an Exempt Issuance:

(1)              
Issuance of Rights or Options. In case at any time the Company shall in any manner grant (directly and not by assumption
in a merger or otherwise) any warrants or other rights to subscribe for or to purchase, or any options for the purchase of, Common
Stock or any stock or security convertible into or exchangeable for Common Stock (such warrants, rights or options being called
“Options” and such convertible or exchangeable stock or securities being called “Convertible
Securities”) whether or not such Options or the right to convert or exchange any such Convertible Securities are immediately
exercisable, and the price per share for which Common Stock is issuable upon the exercise of such Options or upon the conversion
or exchange of such Convertible Securities (determined by dividing (i) the sum (which sum shall constitute the applicable consideration)
of (x) the total amount, if any, received or receivable by the Company as consideration for the granting of such Options, plus
(y) the aggregate amount of additional consideration payable to the Company upon the exercise of all such Options, plus (z), in
the case of such Options which relate to Convertible Securities, the aggregate amount of additional consideration, if any, payable
upon the issue or sale of such Convertible Securities and upon the conversion or exchange thereof, by (ii) the total maximum number
of shares of Common Stock issuable upon the exercise of such Options or upon the conversion or exchange of all such Convertible
Securities issuable upon the exercise of such Options) shall be less than the Exercise Price in effect immediately prior to the
time of the granting of such Options, then the total number of shares of Common Stock issuable upon the exercise of such Options
or upon conversion

     -8-

     

    

or exchange of the total amount
of such Convertible Securities issuable upon the exercise of such Options shall be deemed to have been issued for such price per
share as of the date of granting of such Options or the issuance of such Convertible Securities and thereafter shall be deemed
to be outstanding for purposes of adjusting the Exercise Price. Except as otherwise provided below, no adjustment of the Exercise
Price shall be made upon the actual issue of such Common Stock or of such Convertible Securities upon exercise of such Options
or upon the actual issue of such Common Stock upon conversion or exchange of such Convertible Securities.

(2)              
Issuance of Convertible Securities. In case the Company shall in any manner issue (directly and not by assumption
in a merger or otherwise) or sell any Convertible Securities, whether or not the rights to exchange or convert any such Convertible
Securities are immediately exercisable, and the price per share for which Common Stock is issuable upon such conversion or exchange
(determined by dividing (i) the sum (which sum shall constitute the applicable consideration) of (x) the total amount received
or receivable by the Company as consideration for the issue or sale of such Convertible Securities, plus (y) the aggregate amount
of additional consideration, if any, payable to the Company upon the conversion or exchange thereof, by (ii) the total number of
shares of Common Stock issuable upon the conversion or exchange of all such Convertible Securities) shall be less than the Exercise
Price in effect immediately prior to the time of such issue or sale, then the total maximum number of shares of Common Stock issuable
upon conversion or exchange of all such Convertible Securities shall be deemed to have been issued for such price per share as
of the date of the issue or sale of such Convertible Securities and thereafter shall be deemed to be outstanding for purposes of
adjusting the Exercise Price, provided that (a) except as otherwise provided in subsection (iii) below, no adjustment of the Exercise
Price shall be made upon the actual issuance of such Common Stock upon conversion or exchange of such Convertible Securities and
(b) no further adjustment of the Exercise Price shall be made by reason of the issue or sale of Convertible Securities upon exercise
of any Options to purchase any such Convertible Securities for which adjustments of the Exercise Price have been made pursuant
to the other provisions of this Section 6.

(3)              
Change in Option Price or Conversion Rate. Upon the happening of any of the following events, namely, if the purchase
price provided for in any Option referred to above, the additional consideration, if any, payable upon the conversion or exchange
of any Convertible Securities referred to above, or the rate at which Convertible Securities referred to above are convertible
into or exchangeable for Common Stock shall change at any time (including, but not limited to, changes under or by reason of provisions
designed to protect against dilution), the Exercise Price in effect at the time of such event shall forthwith be readjusted to
the Exercise Price which would have been in effect at such time had such Options or Convertible Securities still outstanding provided
for such changed purchase price, additional consideration or conversion rate, as the case may be, at the time initially granted,
issued or sold. On the termination of any Option for which any adjustment was made pursuant to this Section 6 or any right to convert
or exchange Convertible Securities for which any adjustment was made pursuant to this Section 6 (including without limitation upon
the redemption or purchase for consideration of such Convertible Securities by the Company), the Exercise

     -9-

     

    

Price then in effect hereunder
shall forthwith be changed to the Exercise Price which would have been in effect at the time of such termination had such Option
or Convertible Securities, to the extent outstanding immediately prior to such termination, never been issued.

(4)              
Consideration for Stock. In case any shares of Common Stock, Options or Convertible Securities shall be issued or
sold for cash, the consideration received therefor shall be deemed to be the gross amount received by the Company therefor, before
any deduction therefrom of any expenses incurred or any underwriting commissions or concessions paid or allowed by the Company
in connection therewith. In case any shares of Common Stock, Options or Convertible Securities shall be issued or sold for a consideration
other than cash, the amount of the consideration other than cash received by the Company shall be deemed to be the fair value of
such consideration as determined in good faith by the Board of Directors of the Company, after deduction of any expenses incurred
or any underwriting commissions or concessions paid or allowed by the Company in connection therewith. In case any Options shall
be issued in connection with the issue and sale of other securities of the Company, together comprising one integral transaction
in which no specific consideration is allocated to such Options by the parties thereto, such Options shall be deemed to have been
issued for such consideration as determined in good faith by the Board of Directors of the Company. If Common Stock, Options or
Convertible Securities shall be issued or sold by the Company and, in connection therewith, other Options or Convertible Securities
(the “Additional Rights”) are issued, then the consideration received or deemed to be received by the
Company shall be reduced by the fair market value of the Additional Rights (as determined using a method mutually agreed to by
the Company and the Holder). The Board of Directors of the Company shall respond promptly, in writing, to an inquiry by the Holders
as to the fair market value of the Additional Rights. In the event that the Board of Directors of the Company and the Holders are
unable to agree upon the fair market value of the Additional Rights, the Company and the Holders shall jointly select an appraiser,
who is experienced in such matters. The decision of such appraiser shall be final and conclusive, and the cost of such appraiser
shall be borne evenly by the Company and the Holder.

(5)              
Record Date. In case the Company shall take a record of the holders of its Common Stock for the purpose of entitling
them (i) to receive a dividend or other distribution payable in Common Stock, Options or Convertible Securities or (ii) to subscribe
for or purchase Common Stock, Options or Convertible Securities, then such record date shall be deemed to be the date of the issue
or sale of the shares of Common Stock deemed to have been issued or sold upon the declaration of such dividend or the making of
such other distribution or the date of the granting of such right of subscription or purchase, as the case may be.

7.                 
Pro Rata Distributions. If the Company, at any time prior to the Expiration Date, shall distribute to all holders
of Common Stock (and not to Holders of the Warrants) evidences of its indebtedness or assets (including cash and cash dividends)
or rights or warrants to subscribe for or purchase any security), then in each such case the Exercise Price shall be adjusted by
multiplying the Exercise Price in effect immediately prior to the record date fixed for

     -10-

     

    

determination of stockholders entitled
to receive such distribution by a fraction of which the denominator shall be the Fair Market Value determined as of the record
date mentioned above, and of which the numerator shall be such Fair Market Value on such record date less the then per share Fair
Market Value at such record date of the portion of such assets or evidence of indebtedness so distributed applicable to one outstanding
share of the Common Stock as determined by the Board of Directors in good faith. In either case the adjustments shall be described
in a statement provided to the Holder of the portion of assets or evidences of indebtedness so distributed or such subscription
rights applicable to one share of Common Stock. Such adjustment shall be made whenever any such distribution is made and shall
become effective immediately after the record date mentioned above.

8.                 
Certificate as to Adjustments. In each case of any adjustment or readjustment in the shares of Common Stock (or Other
Securities) issuable on the exercise of this Warrant, the Company at its expense will promptly cause its Chief Financial Officer
or other appropriate designee to compute such adjustment or readjustment in accordance with the terms of this Warrant and prepare
a certificate setting forth such adjustment or readjustment and showing in detail the facts upon which such adjustment or readjustment
is based, including a statement of (a) the consideration received or receivable by the Company for any additional shares of Common
Stock (or Other Securities) issued or sold or deemed to have been issued or sold, (b) the number of shares of Common Stock (or
Other Securities) outstanding or deemed to be outstanding, and (c) the Exercise Price and the number of shares of Common Stock
to be received upon exercise of this Warrant, in effect immediately prior to such adjustment or readjustment and as adjusted or
readjusted as provided in this Warrant. The Company will forthwith mail a copy of each such certificate to the Holder and any warrant
agent of the Company (appointed pursuant to Section 12 hereof).

9.                 
Reservation of Stock, Etc., Issuable on Exercise of Warrant. The Company will at all times reserve and keep available,
solely for issuance and delivery on the exercise of this Warrant, shares of Common Stock (or Other Securities) from time to time
issuable on the exercise of this Warrant.

10.             
Assignment; Exchange of Warrant. Subject to compliance with applicable securities laws, this Warrant, and the rights
evidenced hereby, may be transferred by any registered holder hereof (a “Transferor”) in whole or in part. On the surrender
for exchange of this Warrant, with the Transferor’s endorsement in the form of Exhibit B attached hereto (the “Transferor
Endorsement Form”) and together with evidence reasonably satisfactory to the Company demonstrating compliance with applicable
securities laws, which shall include, without limitation, a legal opinion from the Transferor’s counsel (at the Transferor’s
expense) that such transfer is exempt from the registration requirements of applicable securities laws, the Company at its expense
(but with payment by the Transferor of any applicable transfer taxes) will issue and deliver to or on the order of the Transferor
thereof a new Warrant of like tenor, in the name of the Transferor and/or the transferee(s) specified in such Transferor Endorsement
Form (each a “Transferee”), calling in the aggregate on the face or faces thereof for the number of shares of Common
Stock called for on the face or faces of the Warrant so surrendered by the Transferor.

     -11-

     

    

11.             
Replacement of Warrant. On receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction
or mutilation of this Warrant and, in the case of any such loss, theft or destruction of this Warrant, on delivery of an indemnity
agreement or security reasonably satisfactory in form and amount to the Company or, in the case of any such mutilation, on surrender
and cancellation of this Warrant, the Company at its expense will execute and deliver, in lieu thereof, a new Warrant of like tenor.

12.             
Reserved.

13.             
Warrant Agent. The Company may, by written notice to the Holder of the Warrant, appoint an agent for the purpose
of issuing Common Stock (or Other Securities) on the exercise of this Warrant pursuant to Section 2, exchanging this Warrant pursuant
to Section 9, and replacing this Warrant pursuant to Section 11, or any of the foregoing, and thereafter any such issuance, exchange
or replacement, as the case may be, shall be made at such office by such agent.

14.             
Transfer on the Company’s Books. Until this Warrant is transferred on the books of the Company, the Company
may treat the registered holder hereof as the absolute owner hereof for all purposes, notwithstanding any notice to the contrary.

15.             
Notices, Etc. All notices and other communications from the Company to the Holder shall be mailed by first class
registered or certified mail, postage prepaid, at such address as may have been furnished to the Company in writing by such Holder
or, until any such Holder furnishes to the Company an address, then to, and at the address of, the last Holder who has so furnished
an address to the Company.

16.             
Holder Not Deemed a Stockholder; Limitations on Liability. Except as otherwise specifically provided herein, prior
to the issuance to the Holder of the Common Stock to which the Holder is then entitled to receive upon the due exercise of this
Warrant, the Holder shall not be entitled to vote or receive dividends or be deemed the holder of shares of capital stock of the
Company for any purpose, nor shall anything contained in this Warrant be construed to confer upon the Holder, as such, any of the
rights of a stockholder of the Company or any right to vote, give or withhold consent to any corporate action (whether any reorganization,
issue of stock, reclassification of stock, consolidation, merger, conveyance or otherwise), receive notice of meetings, receive
dividends or subscription rights, or otherwise. In addition, nothing contained in this Warrant shall be construed as imposing any
liabilities on the Holder to purchase any securities (upon exercise of this Warrant or otherwise) or as a stockholder of the Company,
whether such liabilities are asserted by the Company or by creditors of the Company.

17.             
Compliance with the Securities Act. The Holder, by acceptance of this Warrant, agrees to comply in all respects with
the provisions of this Section 17 and the restrictive legend requirements set forth on the face of this warrant and further agrees
that such Holder shall not offer, sell or otherwise dispose of this Warrant or any Common Stock to be issued upon exercise hereof
except under circumstances that will not result in a violation of the Securities Act of 1933, as amended (the “Securities
Act”).

     -12-

     

    

18.             
Miscellaneous. This Warrant and any term hereof may be changed, waived, discharged or terminated only by an instrument
in writing signed by the party against which enforcement of such change, waiver, discharge or termination is sought. THIS WARRANT
SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO PRINCIPLES OF CONFLICTS
OF LAWS. ANY ACTION BROUGHT CONCERNING THE TRANSACTIONS CONTEMPLATED BY THIS WARRANT SHALL BE BROUGHT ONLY IN THE STATE COURTS
OF NEW YORK OR IN THE FEDERAL COURTS LOCATED IN THE STATE OF NEW YORK; PROVIDED, HOWEVER, THAT THE HOLDER MAY CHOOSE TO WAIVE THIS
PROVISION AND BRING AN ACTION OUTSIDE THE STATE OF NEW YORK. The individuals executing this Warrant on behalf of the Company agree
to submit to the jurisdiction of such courts and waive trial by jury. The prevailing party shall be entitled to recover from the
other party its reasonable attorneys’ fees and costs. In the event that any provision of this Warrant is invalid or unenforceable
under any applicable statute or rule of law, then such provision shall be deemed inoperative to the extent that it may conflict
therewith and shall be deemed modified to conform with such statute or rule of law. Any such provision which may prove invalid
or unenforceable under any law shall not affect the validity or enforceability of any other provision of this Warrant. The headings
in this Warrant are for purposes of reference only, and shall not limit or otherwise affect any of the terms hereof. The invalidity
or unenforceability of any provision hereof shall in no way affect the validity or enforceability of any other provision hereof.
The Company acknowledges that legal counsel participated in the preparation of this Warrant and, therefore, stipulates that the
rule of construction that ambiguities are to be resolved against the drafting party shall not be applied in the interpretation
of this Warrant to favor any party against the other party.

[BALANCE OF PAGE INTENTIONALLY LEFT
BLANK;

SIGNATURE PAGE FOLLOWS]

 

     -13-

     

    

IN WITNESS WHEREOF,
the Company has executed this Warrant as of the date first written above.

	 	BIOVIE INC.
	 	 
	 	By:	
 

	 	Name:	
 

	 	Title:	
 

	 	 	 	 	 

 

 

     -14-

     

    

EXHIBIT A

EXERCISE NOTICE

(To Be Signed Only On Exercise Of Warrant)

		TO:	BioVie Inc.

 

Attention:Chief Financial Officer

The undersigned,
pursuant to the provisions set forth in the attached Warrant (No.____) (as amended, restated or otherwise modified from time to
time, the “Warrant”; capitalized terms used but not defined in this notice shall have the meanings ascribed thereto
in the Warrant), hereby irrevocably elects to purchase (check applicable box):

		________	________ shares of the common stock covered by such warrant; or

		________	the maximum number of shares of common stock covered by such warrant pursuant to the cashless exercise
procedure set forth in Section 3.5.

The undersigned
herewith makes payment of the full Exercise Price for such shares at the price per share provided for in such Warrant, which is
$___________. Such payment takes the form of (check applicable box or boxes):

		________	$__________ in lawful money of the United States; and/or

		________	the cancellation of such portion of the attached Warrant as is exercisable for a total of _______
shares of Common Stock (using a Fair Market Value of $_______ per share for purposes of this calculation); and/or

		________	the cancellation of such number of shares of Common Stock as is necessary, in accordance with the
formula set forth in Section 3.5(c), to exercise this Warrant with respect to the maximum number of shares of Common Stock purchasable
pursuant to the cashless exercise procedure set forth in Section 3.5.

The undersigned
requests that the certificates for such shares be issued in the name of, and delivered to ______________________________________________
whose address is ___________________________________________________________________________.

The undersigned
is an “accredited investor” as defined in Regulation D promulgated under the Securities Act of 1933, as amended. The
undersigned represents and warrants that all offers and sales by the undersigned of the securities issuable upon exercise of the
within Warrant shall be made pursuant to registration of the Common Stock under the Securities Act of 1933, as amended (the “Securities
Act”), or pursuant to an exemption from registration under the Securities Act.

	Dated:	
 

	
 

	 	 	(Signature must conform to name of holder as specified on the face of the Warrant)
	 	 	Address:	
 

	 	 	 	
 

 

    	 

    	 

    

EXHIBIT B

FORM OF TRANSFEROR ENDORSEMENT

(To Be Signed Only On Transfer Of Warrant)

For value received,
the undersigned hereby sells, assigns, and transfers unto the person(s) named below under the heading “Transferees”
the right represented by the within Warrant to purchase the percentage and number of shares of Common Stock of BioVie Inc. into
which the within Warrant relates specified under the headings “Percentage Transferred” and “Number Transferred,”
respectively, opposite the name(s) of such person(s) and appoints each such person Attorney to transfer its respective right on
the books of BioVie Inc. with full power of substitution in the premises.

	Transferees	Address	Percentage Transferred	Number 

Transferred
	 	 	 	 
	 	 	 	 
	Dated:	
 

	
 

	 	 	(Signature must conform to name of holder as specified on the face of the Warrant)
	 	 	Address:	
 

	 	 	 	
 

	 	 	SIGNED IN THE PRESENCE OF:
	 	 	
 

	 	 	(Name)
	 	 	 	 	 	 	 

ACCEPTED AND AGREED:

[TRANSFEREE]

___________________________

(Name)

 

NOTE: The signature to this Assignment Form must correspond with
the name as it appears on the face of the Warrant, without alteration or enlargement or any change whatsoever, and must be guaranteed
by a bank or trust company. Officers of corporations and those acting in a fiduciary or other representative capacity should file
proper evidence of authority to assign the foregoing Warrant.

 

    

     

    

Exhibit B

 

Form of Lockup

 

 

 

 

 

 

 

 

 

 

    

     

    
LOCK-UP AGREEMENT (this "Agreement") made
on the 3 day of July, 2018

 

AMONG:

 

		(1)	Acuitas Group Holdings, LLC (the "Investor");

		(2)	Jonathan Adams, Julie Anderson, Cuong Do, Elliot Ehrlich, Leo and Helene Ehrlich, Rebecca Guttman and RGN Brothers
Trust (each, a “Stockholder” and collectively, the "Stockholders").

RECITALS:

 

		(A)	Each Stockholder owns the number of shares of the common stock (the “Common Stock”), par value US$0.0001
per share, of BioVie Inc. (the “Company”) set forth on Exhibit A hereto.

		(C)	Pursuant to the Securities Purchase Agreement (the "Purchase Agreement") dated as of the date hereof by and
among the Investor and the Company, the Company will issue to the Investor, and the Investor will purchase from the Company, the
Preferred Stock and the Warrants, each as defined below, subject to the terms and conditions thereof. Terms used but not defined
herein have the meaning given them in the Purchase Agreement

		(D)	In consideration of and as a condition precedent to the purchase of the Preferred Stock and Warrants by the Investor under
the Purchase Agreement, the Parties (as defined below) enter into this Agreement.

AGREEMENT:

Section
1

INTERPRETATION

		1.1	Definitions. In this Agreement, unless the context otherwise requires, the following words and expressions have the
following meanings:

"1934 Act" means the Securities
Exchange Act of 1934 of the United States of America, as amended, and the rules and regulations promulgated thereunder.

"Affiliate" of a Person (the
"Subject Person") means (a) in the case of a Person other than a natural person, any other Person that directly
or indirectly Controls, is Controlled by or is under common Control with the Subject Person and (b) in the case of a natural person,
any other Person that is directly or indirectly Controlled by the Subject Person or is a Relative of the Subject Person. In the
case of the Investor, the term "Affiliate" includes (v) any shareholder of the Investor, (w) any of such shareholder's
general partners or limited partners, (x) the fund manager managing such shareholder (and general partners, limited partners and
officers thereof) and (y) trusts controlled by or for the benefit of any such individuals referred to in (w) or (x).

    -1-

     

    

"Business Day" means any day other
than a Saturday, Sunday or other day on which commercial banks in New York City are required or authorized by law or executive
order to be closed.

"Company Charter Documents" means
the Articles of Incorporation, as amended, and by-laws of the Company.

"Control" of a Person means (a) ownership
of more than 50% of the shares in issue or other equity interests or registered capital of such Person or (b) the power to direct
the management or policies of such Person, whether through ownership or voting proxy of the voting power of such Person, through
the power to appoint a majority of the members of the board of directors or similar governing body of such Person, through contractual
arrangements or otherwise.

"Encumbrance" means (a) any mortgage,
charge (whether fixed or floating), pledge, lien, hypothecation, assignment, deed of trust, title retention, security interest
or other encumbrance of any kind securing, or conferring any priority of payment in respect of, any obligation of any Person, including
any right granted by a transaction which, in legal terms, is not the granting of security interest or any other encumbrance but
which has an economic or financial effect similar to the granting of security interest or any other encumbrance under applicable
law, (b) any lease, sub-lease, occupancy agreement, easement or covenant granting a right of use or occupancy to any Person, (c)
any proxy, power of attorney, voting trust agreement, interest, option, right of first offer, negotiation or refusal or transfer
restriction in favor of any Person and (d) any adverse claim as to title, possession or use.

"Equity Securities" means, with respect
to any Person, such Person's capital stock, membership interests, partnership interests, registered capital, joint venture or other
ownership interests or any options, warrants or other securities that are directly or indirectly convertible into, or exercisable
or exchangeable for, such capital stock, membership interests, partnership interests, registered capital or joint venture or other
ownership interests (whether or not such derivative securities are issued by such Person). Unless the context otherwise requires,
any reference to "Equity Securities" refers to the Equity Securities of the Company.

"Governmental Authority" means
any government or political subdivision thereof; any department, agency or instrumentality of any government or political subdivision
thereof; any court or arbitral tribunal; and the governing body of any securities exchange, in each case having competent jurisdiction.

"Party" or "Parties"
means any signatory or the signatories to this Agreement and any Person that subsequently becomes a party to this Agreement as
provided herein.

"Person" means any natural person,
firm, company, Governmental Authority, joint venture, partnership, association or other entity (whether or not having separate
legal personality).

    -2-

     

    

"Relative" of a natural person means
the spouse of such person and any parent, grandparent, child, grandchild, sibling, cousin, in-law, uncle, aunt, nephew or niece
of such person or spouse.

		1.2	Interpretation.

		(a)	Directly or Indirectly. The phrase "directly or indirectly" means directly, or indirectly through one
or more intermediate Persons or through contractual or other arrangements, and "direct or indirect" has the correlative
meaning.

		(b)	Gender and Number. Unless the context otherwise requires, all words (whether gender-specific or gender neutral) will
be deemed to include each of the masculine, feminine and neuter genders, and words importing the singular include the plural and
vice versa.

		(c)	Headings. Headings are included for convenience only and will not affect the construction of any provision of this Agreement.

		(d)	Include not Limiting. "Include," "including," "are inclusive of"
and similar expressions are not expressions of limitation and will be construed as if followed by the words "without limitation".

		(e)	Law. References to "law" will include all applicable laws, regulations, rules and orders of any Governmental
Authority, securities exchange or other self-regulating body, any common or customary law, constitution, code, ordinance, statute
or other legislative measure and any regulation, rule, treaty, order, decree or judgment; and "lawful" will be
construed accordingly.

		(f)	References to Documents. References to this Agreement include the Exhibit, which form an integral part hereof. A reference
to any Section, Schedule or Exhibit is, unless otherwise specified, to such Section of, or Schedule or Exhibit to this Agreement.
The words "hereof," "hereunder" and "hereto," and words of like import, unless
the context requires otherwise, refer to this Agreement as a whole and not to any particular Section hereof or Schedule or Exhibit
hereto. A reference to any document (including this Agreement) is, unless otherwise specified, to that document as amended, consolidated,
supplemented, novated or replaced from time to time.

		(g)	Writing. References to writing and written include any mode of reproducing words in a legible and non-transitory form
including emails and faxes.

Section
2

RESTRICTIONS ON TRANSFER OF SHARES

		2.1	Restriction on Transfers. Without the Investor's prior written consent, no Stockholder will, directly or indirectly,

		(a)	sell, give, assign, hypothecate, pledge, encumber, grant a security interest in or otherwise dispose of, or suffer to exist
(whether by operation of law or otherwise) any Encumbrance on, any Equity Securities of the Company directly or indirectly held
by it or any right, title or interest therein or thereto

    -3-

     

    

(including any contractual or other legal arrangement
having the effect of transferring any or all of the benefits of ownership or economic rights), or establish or increase a put equivalent
position or liquidate or decrease a call equivalent position within the meaning of Section 16 of the 1934 Act with respect to any
Equity Securities held by it, or otherwise take any action to the effect that any other Person will become a “beneficial
owner” (as defined in Rule 13d-3 promulgated under the 1934 Act) of any Equity Security held by it; or

		(b)	enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of
ownership of any Equity Securities directly or indirectly held by it or with respect to which it has beneficial ownership within
the rules and regulations of the Securities and Exchange Commission, whether any such transaction is to be settled by delivery
of such securities, in cash or otherwise

(each, a "Transfer").

		2.2	[RESERVED].

		2.3	No Hedging. The restrictions set forth in Section 2.1 are expressly agreed to preclude the Stockholders from engaging
in any hedging or other transaction which is designed to or which reasonably could be expected to lead to or result in a sale or
disposition of any Equity Securities directly or indirectly held by such Stockholders even if such Equity Securities would be disposed
of by someone other than the relevant Stockholder. Such prohibited hedging or other transactions would include, without limitation,
any short sale or any purchase, sale or grant of any right (including, without limitation, any put or call option) with respect
to any Equity Securities held by such Stockholder.

		2.4	Violation of Transfer Restrictions. Any attempt to Transfer any Equity Securities in violation of Section 2 will be
null and void ab initio.

		2.5	Limitation on Transfer Restrictions.

		(a)	The Transfer restrictions set forth in Sections 2.1 and 2.3 will be in full force and effect until October 3, 2018 (the “Termination
Date”).

Section
3

REPRESENTATIONS, WARRANTIES, COVENANTS AND UNDERTAKINGS

		3.1	Representations and Warranties. Each Stockholder represents to the Investor, and the Investor represents to each Stockholder
(to the extent applicable), that:

		(a)	such Party has the full power and authority to enter into, execute and deliver this Agreement and to perform the transactions
contemplated hereby, and, if an entity, such Party is duly incorporated or organized and existing under the laws of the jurisdiction
of its incorporation or organization;

    -4-

     

    

		(b)	if an entity, the execution and delivery by such Party of this Agreement and the performance by such Party of the transactions
contemplated hereby have been duly authorized by all necessary corporate or other action of such Party;

		(c)	assuming the due authorization, execution and delivery hereof by the other Parties, this Agreement constitutes the legal, valid
and binding obligation of such Party, enforceable against such Party in accordance with its terms, except as such enforceability
may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors' rights generally;
and

		(d)	the execution, delivery and performance of this Agreement by such Party and the consummation of the transactions contemplated
hereby will not (i) if any entity, violate any provision of any organizational or governance document of such Party, (ii) require
such Party to obtain any consent, approval or action of, or make any filing with or give any notice to, any Governmental Authority
in such Party’s country of organization or any other Person pursuant to any instrument, contract or other agreement to which
such Party is a party or by which such Party is bound, other than any such consent, approval, action or filing that has already
been duly obtained or made or otherwise explicitly required hereunder, (iii) conflict with or result in any breach or violation
of any of the terms and conditions of, or constitute (or with notice or lapse of time or both constitute) a default under, any
instrument, contract or other agreement to which such Party is a party or by which such Party is bound, or (iv) violate any law.

		3.2	Transaction Documents. Each Stockholder will procure that the Company will perform its obligations under each Transaction
Document to which it is a party. For the purposes of the foregoing, each Stockholder will vote its voting Equity Securities in
the Company, prior to the issuance of the Preferred Stock and Warrants to the Investor, to approve the execution, delivery and
performance by the Company of each such Transaction Document and the consummation of the transactions contemplated thereby to the
extent required.

Section
4

TERM AND TERMINATION

		4.1	Effective Date; Termination. This Agreement will become effective upon execution and will continue in force until the
earlier to occur of (a) the Termination Date, (b) the date on which the Purchase Agreement is terminated in accordance with the
terms thereof and (c) any date agreed upon in writing by all of the Parties.

		4.2	Consequences of Termination. If this Agreement is terminated in accordance with Section 4.1, it will become void and
of no further force and effect, except for the provisions of this Section 4, Section 5 (Notices), Section 6 (Miscellaneous) and
Section 7 (Governing Law and Jurisdiction), provided, however, that such termination will, unless otherwise agreed by the Parties,
be without prejudice to the rights or obligations of any Party accrued under this Agreement prior to such termination.

    -5-

     

    
Section
5

NOTICES

		5.1	Notices. Each notice, demand or other communication given or made under this Agreement will be in writing in English
and delivered or sent to the relevant Party at its address or fax number set out below (or such other address or fax number as
the addressee has by five Business Days' prior notice specified to the other Parties). Any notice, demand or other communication
given or made by letter between countries will be delivered by international commercial overnight delivery service or courier (such
as Federal Express or DHL). Any notice, demand or other communication so addressed to the relevant Party will be deemed to have
been delivered, (i) if delivered in person or by messenger, when proof of delivery is obtained by the delivering party; (ii) if
sent by post within the same country, on the third Business Day following posting, and if sent by post to another country, on the
seventh Business Day following posting; and (iii) if given or made by fax, upon dispatch and the receipt of a transmission report
confirming dispatch.

		5.2	Addresses and Fax Numbers. The initial address and facsimile for each Party for the purposes of this Agreement are:

	if to the Investor:	with a copy to:
	
        Acuitas Group Holdings, LLC

        11601 Wilshire Boulevard

        Suite 1100

        Los Angeles, CA 90025

        Facsimile:

        Attention: Terren Peizer
	Loeb & Loeb LLP

345 Park Avenue

New York, NY 10154

Facsimile: (212) 540-

Attention: Mitchell S. Nussbaum
	if to each Stockholder	with a copy to:
	Jonathan Adams

25-B West 15th St

Chicago, IL 60605	 
	Julie Anderson

3460 R Tern

Boynton Beach, FL33436	 
	Cuong Do

5 India Brook Drive

Mendham, NJ 07945	 
	Elliot Ehrlich

9511 Collins Ave #807

Surfside, FL 33154	 

    -6-

     

    

 

	Leo and Helene Ehrlich

7846 Tennyson Ct.

Boca Raton, FL 33433	 
	Rebecca Guttman

655 Ibsen St.

Woodmere, NY 11598	 
	RGN Brothers Trust

2715 Avenue L

Brooklyn, NY 11210	 

Section
6

MISCELLANEOUS

		6.1	Assignment. This Agreement will inure to the benefit of, and be binding upon, the successors and permitted assigns of
the Parties. Subject to and in accordance with Section 2, Each Stockholder will assign this Agreement or any of their respective
rights or obligations hereunder to any Person. The Investor may assign this Agreement or any of its rights or obligations hereunder
to any of its Affiliates, provided that (a) such assignment is in compliance with applicable securities laws and (b) the Investor
undertakes to promptly notify the other Parties in writing of such assignment.

		6.2	No Partnership. The Parties expressly do not intend hereby to form a partnership, either general or limited, under any
jurisdiction's partnership law. The Parties do not intend to be partners one to another, or partners as to any third party, or
create any fiduciary relationship among themselves, by virtue of their status as parties to this Agreement.

		6.3	Amendment. This Agreement may not be amended, modified or supplemented except by a written instrument executed by each
of the Parties.

		6.4	Waiver. No waiver of any provision of this Agreement will be effective unless set forth in a written instrument signed
by the Party waiving such provision. No failure or delay by a Party in exercising any right, power or remedy under this Agreement
will operate as a waiver thereof, nor will any single or partial exercise of the same preclude any further exercise thereof or
the exercise of any other right, power or remedy. Without limiting the foregoing, no waiver by a Party of any breach by any other
Party of any provision hereof will be deemed to be a waiver of any subsequent breach of that or any other provision hereof.

		6.5	Entire Agreement. This Agreement constitutes the whole agreement between the Parties relating to the subject matter
hereof and supersedes any prior agreements or understandings relating to such subject matter.

		6.6	Severability. Each and every obligation under this Agreement will be treated as a separate obligation and will be severally
enforceable as such and in the event of any obligation or obligations being or becoming unenforceable in whole or in part. To the
extent that any provision or provisions of this

    -7-

     

    

Agreement are unenforceable they will be deemed to
be deleted from this Agreement, and any such deletion will not affect the enforceability of such provisions this Agreement as remain
not so deleted.

		6.7	Consent to Specific Performance. The Parties declare that it is impossible to measure in money the damages that would
be suffered by a Party by reason of the failure by any other Party to perform any of the obligations hereunder. Therefore, if any
Party institutes any action or proceeding to enforce the provisions hereof, any Party against whom such action or proceeding is
brought hereby waives any claim or defense therein that the other Party has an adequate remedy at law, to the extent permitted
by law.

		6.8	Counterparts. This Agreement may be executed in one or more counterparts including counterparts transmitted by telecopier
or facsimile, each of which will be deemed an original, but all of which signed and taken together, will constitute one document.

Section
7

GOVERNING LAW AND JURISDICTION

		7.1	Governing Law. THIS AGREEMENT WILL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK
OF THE UNITED STATES OF AMERICA APPLICABLE TO CONTRACTS TO BE PERFORMED WHOLLY WITHIN SUCH JURISDICTION, WITHOUT REGARD TO THE
PRINCIPLES OF CONFLICTS OF LAW OF ANY JURISDICTION.

		7.2	Submission to Jurisdiction. Each of the Parties hereto (i) submits itself to the non-exclusive jurisdiction of any federal
court located in the State of New York or any New York state court having subject matter jurisdiction in the event any dispute
arises out of this Agreement, (ii) agrees that venue will be proper as to proceedings brought in any such court with respect to
such a dispute, (iii) will not attempt to deny or defeat such personal jurisdiction or venue by motion or other request for leave
from any such court and (iv) agrees to accept service of process at its address for notices pursuant to this Agreement in any such
action or proceeding brought in any such court. With respect to any such action, service of process upon any party hereto in the
manner provided herein for the giving of notices will be deemed, in every respect, effective service of process upon such party.

    -8-

     

    

IN WITNESS WHEREOF, the undersigned
have executed this Agreement as of the date first above written.

 

ACUITAS GROUP HOLDINGS, LLC

 

 

 

		By:	______________________

Name:

Title:

 

 

 

 

______________________

Jonathan Adams

 

 

 

 

______________________

Julie Anderson

 

 

 

 

______________________

Cuong Do

 

 

 

 

______________________

Elliot Ehrlich

 

 

 

 

______________________

Leo and Helene Ehrlich

 

 

 

 

______________________

Rebecca Guttman

    -9-

     

    

RGN
Brothers Trust

 

 

 

By:______________________

Name:

Title:

 

    -10-

     

    

APPENDIX A

 

Current Ownership of Common Stock

 

	Jonathan Adams	 	 	6,113,521	 
	Julie Anderson	 	 	368,500	 
	Cuong Do	 	 	3,038,021	 
	Elliot Ehrlich 	 	 	7,600,000	 
	Leo and Helene Ehrlich 	 	 	8,500,000	 
	Rebecca Guttman 	 	 	8,500,000	 
	RGN Brothers Trust	 	 	8,500,000	 

 

    	 

    	 

    

 

 

 

 

 

LOCK-UP AGREEMENT

among

ACUITAS GROUP HOLDINGS, LLC

and

Stockholders of BioVie, Inc. Party
Hereto

 

________________________________

Dated July 3, 2018

________________________________

 

 

 

 

 

 

 

 

 

 

 

    	 

    	 

    

TABLE OF CONTENTS

Page

	Section 1 INTERPRETATION	1
	Section 2 RESTRICTIONS ON TRANSFER OF SHARES	3
	Section 3 REPRESENTATIONS, WARRANTIES, COVENANTS AND UNDERTAKINGS	4
	Section 4 TERM AND TERMINATION	5
	Section 5 NOTICES	6
	Section 6 MISCELLANEOUS	7
	Section 7 GOVERNING LAW AND JURISDICTION	8

 

 

 

 

 

 

 

 

 

    

     

    

Exhibit C

 

Certificate of Designation

 

 

 

 

    

     

    
 

 

 

    

     

    
 

BioVie
Inc.

CERTIFICATE OF DESIGNATION OF PREFERENCES,

RIGHTS AND LIMITATIONS

OF

SERIES A CONVERTIBLE PREFERRED STOCK

PURSUANT TO SECTION 78.1955 OF THE

NEVADA REVISED STATUTES

The undersigned,
Jonathan Adams, does hereby certify that:

1.       He
is the President and Chief Operating Officer of BioVie Inc., a Nevada corporation (the “Corporation”).

2.       The
Corporation is authorized to issue 10,000,000 shares of preferred stock.

3.       The
following resolutions were duly adopted by the board of directors of the Corporation (the “Board of Directors”):

WHEREAS, the articles
of incorporation of the Corporation (the “Articles”) provides for a class of its authorized stock known as preferred
stock, consisting of 10,000,000 shares, $0.001 par value per share, issuable from time to time in one or more series;

WHEREAS, the Articles
authorizes the Board of Directors to fix and determine the designations, qualifications, limitations and restrictions of the shares
of any series of preferred stock; and

WHEREAS, it is
the desire of the Board of Directors, pursuant to its authority as aforesaid, to fix and determine qualifications, limitations
and restrictions relating to a series of the preferred stock, which shall consist of 2,133,332 shares of the preferred stock which
the Corporation has the authority to issue, as follows:

NOW, THEREFORE,
BE IT RESOLVED, that the Board of Directors does hereby provide for the issuance of a series of preferred stock for cash or exchange
of other securities, rights or property and does hereby fix and determine the rights, preferences, restrictions and other matters
relating to such series of preferred stock as follows:

TERMS OF PREFERRED STOCK

Section
1.                  
Definitions. For the purposes hereof, the following terms shall have the following meanings:

“Affiliate”
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common
control with a Person, as such terms are used in and construed under Rule 405 of the Securities Act.

“Business
Day” means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or
any day on which banking institutions in the State of New York are authorized or required by law or other governmental action to
close.

“Common
Stock” means the Corporation’s common stock, par value $0.0001 per share, and stock of any other class of securities
into which such securities may hereafter be reclassified or changed.

“Conversion
Shares” shall have the meaning set forth in Section 6(a).

“Holders”
shall have the meaning given such term in Section 2.

     -1-

     

    

“Liquidation”
shall have the meaning set forth in Section 5.

“Permitted
Transfer” shall have the meaning set forth in Section 7.

“Person”
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.

“Preferred
Stock” shall have the meaning set forth in Section 2.

“Purchase
Agreement” means the Securities Purchase Agreement, dated on or around July 3, 2018, between the Corporation and the
original Holders, as amended, modified or supplemented from time to time in accordance with its terms.

“Securities
Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

“Trading
Day” means a day on which the principal Trading Market is open for business.

“Trading
Market” means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on
the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market,
the New York Stock Exchange, OTCQB or OTCQX (or any successors to any of the foregoing).

“Transfer”
shall have the meaning set forth in Section 7.

Section
2.                  
Designation, Amount and Par Value. The series of preferred stock shall be designated as Series A Convertible
Preferred Stock (the “Preferred Stock”) and the number of shares so designated shall be 2,133,332 (which shall
not be subject to increase, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other
similar recapitalization with respect to the Preferred Stock, without the written consent of all of the holders of the Preferred
Stock (each, a “Holder” and collectively, the “Holders”)). Each share of Preferred Stock
shall have a par value of $0.001 per share.

Section
3.                  
Dividends. Dividends may be declared and paid on the Preferred Stock from funds legally available as and when
determined by the Board of Directors. The Preferred Stock shall, with respect to the payment of dividends, rank pari passu
with the Common Stock, treating for this purpose all such Preferred Stock as if it had been converted into Common Stock.

Section
4.                  
Voting Rights. Each holder of outstanding shares of Preferred Stock shall be entitled to vote with holders
of outstanding shares of Common Stock, voting together as a single class, with respect to any and all matters presented to the
stockholders of the Corporation for their action or consideration (whether at a meeting of stockholders of the Corporation, by
written action of stockholders in lieu of a meeting or otherwise). In any such vote, each share of Preferred Stock shall be entitled
to that number of votes equal to the number of Conversion Shares each share of Preferred Stock is convertible into pursuant to
Section 6. Each holder of outstanding shares of Preferred Stock shall be entitled to notice of all stockholder meetings (or requests
for written consent) in accordance with the Corporation’s bylaws.

Section
5.                  
Liquidation. Upon any liquidation, dissolution, or winding down of the Corporation (a “Liquidation”),
the Holders shall be entitled to receive out of any remaining assets of the Corporation pari passu with the holders of Common
Stock, pro rata based on the number of shares held by each such holder, treating for this purpose all such Preferred Stock as if
it had been converted into Common Stock. The Corporation shall mail written notice of any such Liquidation, not less than 10 days
prior to the payment date stated therein, to each Holder.

Section
6.                  
Conversion. The outstanding shares of Preferred Stock shall be convertible into Common Stock as follows:

     -2-

     

    

(a)                
Conversion Shares. The number of shares of Common Stock each share of Preferred Stock shall be convertible
into (the “Conversion Rate”) shall initially be one hundred (100) shares of Common Stock (the “Conversion
Shares”). In the event that the Per Share Purchase Price is adjusted pursuant to Section 2.4(a) of the Purchase Agreement,
then the “Conversion Rate” shall be equal to (i) the Conversion Rate multiplied by (ii) the ratio of (A) the
initial Per Share Purchase Price (as defined in the Purchase Agreement) as the numerator and (B) the Per Share Purchase Price as
adjusted pursuant to Section 2.4(a) of the Purchase Agreement as the denominator.

(b)               
Mandatory Conversion. Upon the filing of a Certificate of Amendment to the Articles that increases the number
of authorized shares of Common Stock to 800,000,000, the Corporation shall deliver a written notice to Holders to convert all of
such Holder’s Preferred Stock. The Corporation shall promptly deliver the Conversion Shares required to be delivered by the
Corporation under Section 6(a) to each Holder. Such conversion shall be deemed to have been made immediately prior to the close
of business on the date of such delivery of shares of Common Stock, and the person entitled to receive the shares of Common Stock
issuable upon such conversion shall be treated for all purposes as the record holder of such shares of Common Stock on such date.

(c)                
Consolidation, Merger, Sale, Etc. In case the Corporation shall (a) effect a reorganization, (b) consolidate
with or merge into any other person, or (c) transfer all or substantially all of its properties or assets to any other person under
any plan or arrangement contemplating the dissolution of the Corporation, then, in each such case, as a condition to the consummation
of such a transaction, proper and adequate provision shall be made whereby each share of Preferred Stock shall, after such transaction,
be convertible into the kind and number of shares of stock or other securities or property of the Corporation or of the corporation
resulting from such transaction, or to which assets shall have been sold in such transaction, to which the holder of shares of
Preferred Stock would have been entitled if it had held the Common Stock issuable upon the conversion of such shares of Preferred
Stock on the record date, or, if none, immediately prior to such transaction, at the Conversion Rate in effect on such date. The
provisions of this Section 6(c)) shall similarly apply to successive transactions.

(d)               
Stock Dividends, Splits, Combinations and Reclassifications. If the Corporation shall (i) declare a dividend
or other distribution payable in securities, (ii) split its outstanding shares of Common Stock into a larger number, (iii) combine
its outstanding shares of Common Stock into a smaller number, or (iv) increase or decrease the number of shares of its capital
stock in a reclassification of the Common Stock (including any such reclassification in connection with a merger, consolidation
or other business combination in which the Corporation is the continuing entity) (any such corporate event, an “Event”),
then in each instance the Conversion Rate shall be adjusted such that the number of shares issued upon conversion of one share
of Preferred Stock will equal the number of shares of Common Stock that would otherwise (but for the provisions of this Section
6(d)) be issuable on such conversion multiplied by a fraction of which (a) the numerator is the number of shares of Common Stock
the holder of the Preferred Stock would have held following such Event if it had held the number of shares of Common Stock issuable
upon the conversion of one share of Preferred Stock on the relevant record date relating to such Event, and (b) the denominator
is the number of shares of Common Stock that would otherwise (but for the provisions of this Section 6(d)) be issuable upon the
conversion of one share of Preferred Stock.

(e)                
Reservation of Stock. The Corporation shall, to the extent such shares are available, at all times when any
shares of Preferred Stock shall be outstanding, reserve and keep available out of its authorized but unissued stock, such number
of shares of Common Stock as shall from time to time be sufficient to effect the conversion of all outstanding shares of Preferred
Stock.

 

Section
7.                  
Transfer Restrictions. No Holder of Preferred Stock may sell, assign, transfer, pledge, encumber or in any
manner dispose of the shares of Preferred Stock or any right or interest therein (including without limitation a voting proxy),
whether voluntarily or by operation of law, or by gift or otherwise (a “Transfer”), other than by means of a
Permitted Transfer. Any Transfer, or purported Transfer, of Preferred Stock of the Corporation other than a Permitted Transfer
shall be null and void, and of no force or effect; provided that the Board of Directors may at its sole discretion waive any or
all of the foregoing conditions through prior written

     -3-

     

    

consent. The only transaction
that is a “Permitted Transfer” is a Transfer that meets the following conditions: (i) the Transfer by a Holder
must be to an Affiliate of such Holder or to the Corporation, and (ii) the Transfer must comply with all applicable securities
laws including, without limitation, the federal securities laws of the United States.

Section
8.                  
Miscellaneous.

(a)                
Notices. Any and all notices or other communications or deliveries to be provided by the Holders hereunder
shall be in writing and delivered personally, by facsimile, or sent by a nationally recognized overnight courier service, addressed
to the Corporation, Attention: Jonathan Adams, 25 West 15th Street, Unit B, Chicago, IL 60605, facsimile number 708-716-3027,
or such other facsimile number or address as the Corporation may specify for such purposes by notice to the Holders delivered in
accordance with this Section. Any and all notices or other communications or deliveries to be provided by the Corporation hereunder
shall be in writing and delivered personally, by facsimile, or sent by a nationally recognized overnight courier service addressed
to each Holder at the facsimile number or address of such Holder appearing on the books of the Corporation, or if no such facsimile
number or address appears on the books of the Corporation, at the principal place of business of such Holder, as set forth in the
Purchase Agreement. Any notice or other communication or deliveries hereunder shall be deemed given and effective on the earliest
of (i) the date of transmission, if such notice or communication is delivered via facsimile at the facsimile number or email attachment
at the email address as set forth on the signature pages attached hereto at or prior to 5:30 p.m. (New York City time) on a Trading
Day, (ii) the next Trading Day after the date of transmission, if such notice or communication is delivered via facsimile at the
facsimile number or email attachment at the email address as set forth on the signature pages attached hereto on a day that is
not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (iii) the second (2nd) Trading Day
following the date of mailing, if sent by U.S. nationally recognized overnight courier service or (iv) upon actual receipt by the
party to whom such notice is required to be given.

(b)               
Governing Law. All questions concerning the construction, validity, enforcement and interpretation of this
Certificate of Designation shall be governed by and construed and enforced in accordance with the internal laws of the State of
Nevada, without regard to the principles of conflict of laws thereof. Each party hereto hereby irrevocably waives, to the fullest
extent permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or relating to this
Certificate of Designation or the transactions contemplated hereby. If any party shall commence an action or proceeding to
enforce any provisions of this Certificate of Designation, then the prevailing party in such action or proceeding shall be reimbursed
by the other party for its attorneys’ fees and other costs and expenses incurred in the investigation, preparation and prosecution
of such action or proceeding.

(c)                
Waiver. Any waiver by the Corporation or a Holder of a breach of any provision of this Certificate of Designation
shall not operate as or be construed to be a waiver of any other breach of such provision or of any breach of any other provision
of this Certificate of Designation or a waiver by any other Holders. The failure of the Corporation or a Holder to insist upon
strict adherence to any term of this Certificate of Designation on one or more occasions shall not be considered a waiver or deprive
that party (or any other Holder) of the right thereafter to insist upon strict adherence to that term or any other term of this
Certificate of Designation on any other occasion. Any waiver by the Corporation or a Holder must be in writing.

(d)               
No Impairment. The Corporation shall not, by amendment of its articles of incorporation or through any reorganization,
sale, exchange or other disposition of assets, merger, consolidation, dissolution, issue or sale of securities, or any other voluntary
action, avoid or seek to avoid the observance or performance of any of the terms to be observed or performed under Section 6 by
the Corporation, but will at all times in good faith carry out all the provisions of Section 6 and take all such action as may
be necessary or appropriate in order to protect the conversion rights of the holders of Preferred Stock against impairment.

     -4-

     

    

(e)                
Notices of Record Date. In the event any record date is fixed for the purpose of (i) determining the holders
of any class or series of stock or other securities who are entitled to receive any dividend or other distribution or (ii) any
recapitalization or reorganization of the capital stock of the Corporation, any merger or consolidation of the Corporation, or
any sale, exchange or other disposition of all or substantially all the assets of the Corporation or any voluntary or involuntary
dissolution, liquidation or winding up of the Corporation, the Corporation shall mail to each holder of Preferred Stock at least
twenty (20) days prior to the record date set forth therein a notice setting forth: (A) such record date and a description of such
dividend or distribution; (B) the date on which any such recapitalization, reorganization, merger, consolidation, disposition,
dissolution, liquidation or winding up is expected to become effective; and (C) the time, if any is to be fixed, as to when the
holders of record of Common Stock (or other securities) shall be entitled to exchange their shares of Common Stock (or other securities)
for securities or other property deliverable upon such recapitalization, reorganization, merger, consolidation, disposition, dissolution,
liquidation or winding up.

(f)                 
Severability. If any provision of this Certificate of Designation is invalid, illegal or unenforceable, the
balance of this Certificate of Designation shall remain in effect, and if any provision is inapplicable to any Person or circumstance,
it shall nevertheless remain applicable to all other Persons and circumstances. If it shall be found that any interest or other
amount deemed interest due hereunder violates the applicable law governing usury, the applicable rate of interest due hereunder
shall automatically be lowered to equal the maximum rate of interest permitted under applicable law.

(g)               
Next Business Day. Whenever any payment or other obligation hereunder shall be due on a day other than a Business
Day, such payment shall be made on the next succeeding Business Day.

(h)               
Headings. The headings contained herein are for convenience only, do not constitute a part of this Certificate
of Designation and shall not be deemed to limit or affect any of the provisions hereof.

(i)                 
Status of Converted or Redeemed Preferred Stock. Shares of Preferred Stock may only be issued pursuant to
the Purchase Agreement. If any shares of Preferred Stock shall be converted, redeemed or reacquired by the Corporation, such shares
shall resume the status of authorized but unissued shares of preferred stock and shall no longer be designated as Series A Convertible
Preferred Stock.

RESOLVED, FURTHER,
that the president or any vice-president, and the secretary or any assistant secretary, of the Corporation be and they hereby are
authorized and directed to prepare and file this Certificate of Designation of Preferences, Rights and Limitations in accordance
with the foregoing resolution and the provisions of Nevada law.

*****

(Signature page
follows)

     -5-

     

    

IN WITNESS WHEREOF,
the undersigned has executed this Certificate of Designation this 2nd day of July, 2018.

 

 

/s/ Jonathan Adams

Name:        Jonathan
Adams

Title:        Chief
Executive Officer

 

 

     -6-

     

    

 

 

 

	 

 

 

 

DISCLOSURE SCHEDULE

 

to the

 

SECURITIES PURCHASE AGREEMENT

between

BIOVIE INC.,

ACUITAS GROUP HOLDINGS, LLC

and

THE PURCHASERS IDENTIFIED ON THE SIGNATURES
PAGES THERETO

dated as of July 3, 2018

 

 

This Disclosure Schedule (the “Disclosure
Schedule”) is attached and made part of the Securities Purchase Agreement, dated July 3, 2018 (the “Agreement”),
between BioVie Inc., a Nevada corporation (the “Company”), Acuitas Group Holdings, LLC (“Acuitas”)
and the purchasers identified on the signature pages hereto (together with Acuitas, collectively, the “Purchasers”).
Headings have been assigned to the various sections of this Disclosure Schedule for reference purposes only. Capitalized terms
not defined herein shall have the meanings ascribed to them in the Agreement. This Disclosure Schedule includes brief descriptions
or summaries of certain agreements and instruments. Such descriptions do not purport to be comprehensive, and are qualified in
their entirety by reference to the text of the documents described.

 

	 

 

 

    	 

    	 

    

Section 3.1(a)

 

Subsidiaries

 

	Company	Jurisdiction of Organization
	LAT Pharma LLC	Illinois

 

Brief description:

On April 11, 2016, LAT Pharma LLC merged with and into LAT Acquisition
Corp., a Nevada corporation and wholly-owned subsidiary of BioVie, Inc. f/k/a NanoAntibiotics, Inc., a Nevada corporation, with
LAT Pharma LLC as the surviving entity.

 

    	 

    	 

    

Section 3.1(g) 

 

Capitalization

 

(i)

 

BioVie common share issuances from 3/31/2018 through the Closing
Date:

 

 

 

    	 

    	 

    

(ii)

 

BioVie common share warrants outstanding as of the Closing Date:

 

 

 

 

 

    	 

    	 

    

BioVie common share options outstanding as of the Closing Date:

 

 

 

 

 

 

    	 

    	 

    

 

Section 3.1(i) 

 

Material Changes; Undisclosed Events, Liabilities
or Developments

 

(i)

 

Item 1 of Section 3.1(j) is incorporated by reference.

 

(ii)

 

Pursuant to the Agreement and Plan of Merger entered into on April
11, 2016 between LAT Pharma LLC and NanoAntibiotics, Inc., BioVie is obligated to pay a royalty on the net sales of BIV201 (continuous
infusion terlipressin) in the amount of five percent (5%) to be allocated as follows: four percent (4%) to LAT Pharma Members,
four-tenths percent (0.4%) to PharmaIn Corporation; and sixth-tenths percent (0.6%) to The Barrett Edge, Inc.

 

Pursuant to the Technology Transfer Agreement entered into on July
25, 2016 between BioVie and the University of Padova (Italy), BioVie is obligated to pay a royalty of 5% on net sales of all terlipressin
products covered by US patent no. 9,655,645 and any future foreign issuances capped at no more than $200,000 per year.

 

(iii)

 

None.

 

(iv)

 

None.

 

(v)

 

None.

 

    	 

    	 

    

Section 3.1(j)

 

Litigation

 

 

 

		1.	On April 30, 2018, BioVie learned that Mallincrkrodt Pharmaceuticals Ireland Limited had filed a petition before the US Patent
Trial and Appeal Board via the inter partes review (IPR) process to challenge our US patent no. 9,655,645, claiming that
our invention was obvious to a person skilled in the art (“POSITA”). BioVie believes that Mallinckrodt’s arguments
provided have no merit and will seek dismissal of action.

 

 

    	 

    	 

    

Section 3.1(v)

 

Registration Rights

 

 

		1.	On January 4, 2017, BioVie entered into a Registration Right Agreement with the Aspire Capital Fund, LLC. Pursuant to this
Agreement, BioVie filed an S-1 and S-1/A registration statement with the SEC registering for sale 25,000,000 shares of Common Stock
that could be sold to Aspire via the Common Stock Purchase Agreement (the “Equity Line”). The S-1/A Registration became
effective on March 30, 2017.

 

BioVie has the option to terminate the Equity Line
for any reason by delivering notice to Aspire, such notice shall not be effective until one (1) Business Day after it has been
received by Aspire.

 

		2.	On November 30, 2017, BioVie entered into a Piggyback Registration Rights Agreement with Warberg WF V LP, Option Opportunities
Corp. and Serenity Now LLC (the “Shareholders”) covering the purchase of a total of 2.5 million Warrant shares by these
entities. If at any time prior to January 1, 2019, BIVI proposes to register any shares of its common stock under the Securities
Act and the registration form to be used may be used for the registration of Registrable Shares (a “Piggyback Registration”),
BIVI shall promptly give written notice to all holders of Registrable Shares shall include in the registration all Registrable
Shares in respect of which BioVie has received written requests for inclusion within 20 days after receipt of BIVI’s notice.

 

During the term of the above Warrants, BioVie shall have
the option to call 50% of the Warrants issued hereunder for $0.08 per warrant and the Holder shall have the option to put back
50% of the Warrants issued hereunder for $.08 per warrant.

 

 

 

    	 

    	 

    

Section 3.1(aa) 

 

Solvency

 

 

The amount of outstanding indebtedness set forth on Section
4.7 is incorporated by reference.

 

 

    	 

    	 

    

Section 4.7 

 

Use of Proceeds

 

 

The Net Proceeds from the sale securities hereunder shall
be used for working capital and other ordinary operation activities, except for the retirement of the following debts within 5
business days of the Closing:

    	 

    	 

    

 

Section 4.13

 

Certain Transactions and Confidentiality

 

The Company does not have an insider trading policy. However,
the Company’s directors, officer or employees who have access to material, non-public information are not permitted to use
that information for stock trading purposes or for any purposes unrelated to the Company’s business. It is also against the
law to trade or to “tip” others who might make an investment decision based on inside company information. For example,
using non-public information to buy or sell the Company stock, options in the Company stock or the stock of any Company supplier,
customer or competitor is prohibited. The consequences of insider trading violations can be severe. These rules also
apply to the use of material, nonpublic information about other companies (including, for example, our customers, competitors and
potential business partners). In addition to employees, these rules apply to an employee’s spouse, children, parents and
siblings, as well as any other family members living in the employee’s home.PubCo
        Reporting Solutions, Inc.

        6800
        SW 40th St Ste 213

        Miami,
        FL 33155

        Tel:
        (305) 396-1415

        www.PubCoReporting.com

 

June
19, 2018

 

	Daniel
    Weadock	Sent
    Via Email

Indoor
Harvest Corp

5300A
East Freeway

Houston,
TX 77020

 

Dear
Mr. Weadock:

 

This
will confirm our understanding of the arrangements made with you covering the SEC reporting services PubCo Reporting Solutions,
Inc. (the “Firm”, “PubCo Reporting”) will perform for Indoor Harvest Corp (the “Company”,
“Indoor Harvest”).

 

Accounting
Services:

 

	 	●	Consolidated
    financial statement preparation and required schedules for the Company and its subsidiaries.
	 	●	Assistance
    with any bookkeeping as required for the Company and its subsidiaries.
	 	●	Liaison
    with auditor for quarterly reviews and annual audit.
	 	●	Assistance
    with md&a preparation and/or review of SEC reporting documents, such as, Form 10-Q, and 10-K.
	 	●	Fees
    for the engagement will consist of an hourly rate of $65 to $150 depending on the level of staff member required to complete
    the tasks.
	 	●	Our
    estimated fees are $3,500 to $5,000 per quarter.

 

Our
staff and consultants will be available for additional questions and advice during the time of this engagement letter.

 

We
will advise you about SEC reporting requirements and their applications as needed, but the responsibility for any reporting commitments
and disclosure remains with the Company and consultation with qualified SEC legal counsel. Management is also responsible for
identifying and ensuring that the Company complies with applicable laws and regulations.

 

We
require a deposit of $3,500.00 to be paid in advance of each quarterly work to be applied to fees as billed. The fees are based
on anticipated cooperation from your personnel and the assumption unexpected circumstances will not be encountered during the
engagement. If significant additional time is necessary, we will discuss it with you and advise of a fee estimate before we incur
the additional costs. Either party can cancel this engagement at any time, with written notice.

 

Our
invoices are due and payable upon presentation except any balances which have been agreed to be paid over a payment schedule at
our discretion. In the event our firm resigns or is dismissed, any unpaid balance due will be required to be paid in full.

 

We
retain the right to suspend or terminate our service in the event of nonpayment. Services will not be resumed until your account
is paid as agreed. If we elect to terminate our services for nonpayment, our engagement will be deemed to have been completed.
The Company will be obligated to compensate us for all time expended and projects completed through the date of termination.

 

    	 

    	 

    

 

Indoor
Harvest Corp

June
19, 2018

Page
2 of 3

 

 

 

The
Firm’s maximum liability relating to services rendered under this letter (regardless of form of action, whether in contract,
negligence or otherwise) shall be limited to the charges paid to the Firm for the portion of its services or work products giving
rise to liability. In no event shall PubCo Reporting, or its personnel, be liable for consequential, special, incidental or punitive
loss, damage or expenses (including without limitation, lost profits, opportunity costs, etc.), even if it has been advised of
their possible existence.

 

During
the course of our engagement, we may need to electronically transmit confidential information to each other and to outside specialists
or other entities engaged by either PubCo Reporting or the Company. E-mail is a fast and convenient way to communicate. However,
e-mail travels over the public Internet, which is not a secure means of communication and, thus confidentiality could be compromised.
The Company agrees to the use of e-mail and other electronic methods to transmit and receive information including confidential
information, between PubCo Reporting, the Company and outside specialists or other entities engaged by either PubCo Reporting
or the Company.

 

The
undersigned agrees that facsimile and electronic signatures shall have the same force and effect under law as if they were originals
and represents that undersigned has the full legal authority to execute this agreement on the Company’s behalf.

 

The
laws of the State of Washington will govern this agreement.

 

If
any portion of this letter is held invalid, it is agreed that such invalidity shall not affect any of the remaining portions.

 

We
appreciate the opportunity to be of service and believe this letter accurately summarizes the significant terms of our engagement.
If you have any questions, please let us know. If you agree with the terms of our engagement as described in this letter, please
sign and return the letter to us.

 

(Signature
page to follow)

 

    	 

    	 

    

 

Indoor
Harvest Corp

June
19, 2018

Page
3 of 3

 

 

 

IN
WITNESS WHEREOF the Parties have duly executed this Agreement as of June 19, 2018.

 

	PubCo
    Reporting Solutions, Inc.	 	UNDERSTOOD
    AND AGREED:
	 	 	 
	 	 	 
	Nanuk
    Warman	 	Name:
	President

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00285-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00285-of-00352.parquet"}]]